



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/178720/>

Version: Accepted Version

Article:

Niedbalski, P.J., Hall, C.S., Castro, M. et al. (2021) Protocols for multi-site trials using hyperpolarized ^{129}Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the ^{129}Xe MRI clinical trials consortium. *Magnetic Resonance in Medicine*, 86 (6). pp. 2966-2986. ISSN: 0740-3194

<https://doi.org/10.1002/mrm.28985>

This is the peer reviewed version of the following article: Niedbalski, PJ, Hall, CS, Castro, M, et al. Protocols for multi-site trials using hyperpolarized ^{129}Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the ^{129}Xe MRI clinical trials consortium. *Magn Reson Med*. 2021, which has been published in final form at <https://doi.org/10.1002/mrm.28985>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley's version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Protocols for Multi-Site Trials using Hyperpolarized ^{129}Xe MRI for Imaging of Ventilation, Alveolar-airspace size, and Gas Exchange: A Position Paper from the ^{129}Xe MRI Clinical Trials Consortium

Peter J. Niedbalski^{1*}, Chase S. Hall¹, Mario Castro¹, Rachel L. Eddy², Jonathan H. Rayment³, Sarah Svenningsen³, Grace Parraga⁴, Brandon Zanette⁵, Giles E. Santyr^{5,6}, Robert P. Thomen⁷, Neil J. Stewart⁸, Guilhem J. Collier⁸, Ho-Fung Chan⁸, Jim M. Wild⁸, Sean B. Fain⁹, G. Wilson Miller¹⁰, Jaime F. Mata¹⁰, John P. Mugler III¹⁰, Bastiaan Driehuys¹¹, Matthew M. Willmering¹², Zackary I. Cleveland^{12,13}, Jason C. Woods^{12,13}

¹Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA

²Centre for Heart Lung Innovation, St. Paul's Hospital; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

³Division of Respiratory Medicine, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada

³Firestone Institute for Respiratory Health, St Joseph's Healthcare; Department of Medicine, Division of Respirology, McMaster University, Hamilton, Ontario, Canada

⁴Robarts Research Institute, Western University, London, Ontario, Canada.

⁵Translational Medicine Program, Hospital for Sick Children, Toronto, Ontario, Canada.

⁶Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

⁷Departments of Radiology and Bioengineering, University of Missouri, Columbia, Missouri, USA

⁸POLARIS, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK

⁹Departments of Medical Physics, Radiology, and Biomedical Engineering, University of Wisconsin, Madison, Wisconsin, USA

¹⁰Center for In-vivo Hyperpolarized Gas MR Imaging, Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, USA

¹¹Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA

¹²Center for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

¹³Departments of Pediatrics (Pulmonary Medicine) and Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

*Corresponding Author:

Peter J. Niedbalski
3901 Rainbow Blvd. Lied 3043
Kansas City, KS 66160
913-588-2271
pniedbalski@kumc.edu

Word Count: 7183

Figures + Tables: 13

1
2
3 **Abstract:** Hyperpolarized (HP) ^{129}Xe MRI uniquely images pulmonary ventilation, gas exchange,
4 and terminal airway morphology rapidly and safely, providing novel information not possible using
5 conventional imaging modalities or pulmonary function tests. As such, there is mounting interest
6 in expanding the use of biomarkers derived from HP ^{129}Xe MRI as outcome measures in multi-
7 site clinical trials across a range of pulmonary disorders. Until recently, HP ^{129}Xe MRI techniques
8 have been developed largely independently at a limited number of academic centers, without
9 harmonizing acquisition strategies. To promote uniformity and adoption of HP ^{129}Xe MRI more
10 widely in translational research, multi-site trials, and ultimately clinical practice, this position paper
11 from the ^{129}Xe MRI Clinical Trials Consortium (<https://cpir.cchmc.org/XeMRITC>) recommends
12 standard protocols to harmonize methods for image acquisition in HP ^{129}Xe MRI.
13 Recommendations are described for the most common HP gas MRI techniques — calibration,
14 ventilation, alveolar-airspace size, and gas exchange — across MRI scanner manufacturers most
15 used for this application. Moreover, recommendations are described for ^{129}Xe dose volumes and
16 breath-hold standardization to further foster consistency of imaging studies. The intention is that
17 sites with HP ^{129}Xe MRI capabilities can readily implement these methods to obtain consistent
18 high-quality images that provide regional insight into lung structure and function. While this
19 document represents consensus at a snapshot in time, a roadmap for technical developments is
20 provided that will further increase image quality and efficiency. These standardized dosing and
21 imaging protocols will facilitate the wider adoption of HP ^{129}Xe MRI for multi-site pulmonary
22 research.
23
24
25
26
27
28
29
30
31
32
33

34
35 **KEYWORDS:** Hyperpolarized ^{129}Xe , Ventilation, Diffusion, Gas Exchange, Protocol
36 Standardization
37
38
39
40

41 1. INTRODUCTION

42
43
44 Over the last 30 years, hyperpolarized (HP) gas magnetic resonance imaging (MRI) with the
45 stable isotopes ^3He and ^{129}Xe has been developed to allow the non-invasive 3D characterization
46 of pulmonary function, with ^{129}Xe seeing increasingly greater usage in the last decade (1,2). HP
47 ^{129}Xe has most commonly been used to image and quantify regional ventilation distribution (3)
48 and assess alveolar microstructure through the restricted self-diffusion of gas within pulmonary
49 airspaces (2). Xenon gas is also soluble in blood and other pulmonary tissues (Ostwald solubility
50 10-20%) (4), and exhibits distinct chemical shifts for ^{129}Xe in different compartments
51 corresponding to gaseous (0 ppm), dissolved in red blood cells (RBCs, 218 ppm), and dissolved
52
53
54
55
56
57
58
59
60

1
2
3 in pulmonary interstitium and blood plasma (197 ppm) (5). This peak at 197 ppm encompasses
4 signal from all non-RBC pulmonary tissues and has at times been referred to as the “barrier” or
5 “tissue/plasma” peak. Recent work (6) has shown that the 197 ppm peak appears to reflect on
6 the membrane component of diffusing capacity, suggesting that this peak may fittingly be called
7 the “membrane” peak. Ultimately, there is a lack of consensus regarding a convenient, intuitive,
8 and physiologically accurate shorthand for this peak at 197 ppm. For the time being, the term
9 “tissue/plasma” will be used throughout this position paper. Regardless of naming conventions,
10 the unique chemical shifts of hyperpolarized ^{129}Xe allow pulmonary gas exchange to be quantified
11 utilizing whole-lung ^{129}Xe MR spectroscopic (MRS) measures of “dissolved-phase” xenon (7-9).
12 Recent advancements have enabled gas, RBC, and tissue/plasma ^{129}Xe to be imaged 3-
13 dimensionally using MR spectroscopic imaging (MRSI) (7,10-13).

14
15
16
17
18
19
20
21 Imaging of ventilation, alveolar-airspace size, and gas exchange using HP ^{129}Xe MRI has shown
22 sensitivity to altered lung microstructure and/or abnormal lung function in a wide variety of
23 pulmonary diseases, including cystic fibrosis (14-18), asthma (19-22), chronic obstructive
24 pulmonary disease (COPD) (19,23-30), lymphangioliomyomatosis (LAM) (31), pulmonary
25 hypertension (32,33), and idiopathic pulmonary fibrosis (IPF) (9,33-37). In addition to showing
26 sensitivity to pulmonary microstructure and function, excellent safety and tolerability of HP ^{129}Xe
27 MRI has been demonstrated in both pediatric and adult patients (38-40). In the UK, Medicines
28 and Healthcare products Regulatory Agency (MHRA) approval was obtained for routine
29 diagnostic use in 2015 at the University of Sheffield for manufacture of HP gases for clinical MRI
30 indications, which has led to >500 patient referrals nationwide to date through the National Health
31 Service. In the United States, phase-III clinical trials were successfully completed in January 2020
32 and a new drug application (NDA) has been filed, with Food and Drug Administration (FDA)
33 approval anticipated in 2021 (41,42). Health Canada approval is expected to follow FDA approval.
34 As a non-invasive technique, that is free of ionizing radiation and exhibits excellent reproducibility
35 and high sensitivity to regional abnormalities, HP ^{129}Xe MRI is ideally suited for use in clinical trials
36 evaluating the efficacy of novel therapies and in clinical care where precise identification of
37 changes in regional lung function are beneficial.

38
39
40
41
42
43
44
45
46
47
48
49 There are several remaining limitations to widespread dissemination of hyperpolarized ^{129}Xe MRI.
50 As a relatively new imaging technology, HP ^{129}Xe MRI is currently limited to ~20 research sites
51 worldwide. Given the increased availability of polarizer systems from commercial and academic
52 manufacturers (43,44), and resolution of regulatory barriers for clinical and research applications
53 in the US and UK, arguably the largest remaining challenge is to harmonize acquisition strategies
54
55
56
57
58
59
60

1
2
3 and quantitative measurement methods into uniformly accepted imaging and analysis protocols
4 across current (and emerging) sites. Necessarily, the early focus in the field was centered on
5 imaging technique development that has occurred largely independently at individual research
6 sites. Moreover, as a multinuclear technique, manufacturer support has historically been
7 inconsistent, and has required sites to develop imaging sequences and protocols from software
8 optimized for conventional proton MRI. As such, there are currently no protocols for imaging
9 ventilation, alveolar-airspace size, or gas exchange that are uniformly used across all ^{129}Xe
10 imaging sites and MRI vendors. To address this gap, this position paper proposes dosing
11 strategies, ^{129}Xe image biomarkers (Table 1), protocols for dissolved ^{129}Xe spectroscopy/scanner
12 calibration, and imaging of HP ^{129}Xe ventilation, alveolar-airspace size, and gas exchange that
13 can be acquired in a breath-hold and have been endorsed for imaging adult subjects by the ^{129}Xe
14 MRI Clinical Trials Consortium (<https://cpir.cchmc.org/XeMRICTC>). This group is dedicated to
15 facilitating clinical research, education, and awareness of the capabilities of ^{129}Xe MRI. Given the
16 focus on harmonization, the proposed protocols necessarily omit some novel techniques and
17 recent innovations. We thus provide a roadmap for such continued innovation and advancement,
18 while herein providing protocols that can be readily and broadly implemented to reduce variation
19 and potential error.
20
21
22
23
24
25
26
27
28
29

30 **2. BACKGROUND**

31
32
33 The various HP ^{129}Xe MRI methods are commonly classified according to the aspect of lung
34 physiology being measured: Ventilation, alveolar-airspace size (commonly restricted diffusion or
35 apparent diffusion coefficient, ADC-mapping), and gas exchange (Table 1). In the sections to
36 follow, we provide detailed recommendations related to pulse sequence and protocol settings for
37 imaging each of these contrasts in adults. We begin with a brief literature review that provides
38 motivation for our specific recommendations.
39
40
41
42

43 **2.1 Calibration**

44
45 In conventional proton (^1H) MRI, essential acquisition parameters, including transmitter power,
46 excitation frequency, and receiver frequency are typically calibrated using vendor-supplied,
47 automated protocols. Unfortunately, these are not applicable to imaging ^{129}Xe , because signal is
48 only present after the administration of hyperpolarized ^{129}Xe and because, unlike traditional
49 thermally polarized ^1H , HP ^{129}Xe signal depletes with time and RF excitation without recovery.
50 Quality assurance can be performed using thermally polarized, pressurized xenon phantoms prior
51 to human imaging (See Supporting Information S1.1) (45), but this does not provide any
52
53
54
55
56
57
58
59
60

1
2
3 information about dissolved-phase xenon, patient-specific coil loading, or the center frequency of
4 ^{129}Xe signal in the locally heterogeneous environment of the lungs.
5

6
7 The resonance frequency for gas-phase ^{129}Xe can be estimated to within ± 20 Hz at 3 Tesla by
8 dividing the proton resonance frequency by the ratio of the $^1\text{H}/^{129}\text{Xe}$ gyromagnetic ratios
9 (3.61529). Similarly, a reasonable estimate of transmit voltages can be made by scaling to patient
10 weight or from transmit power required for proton imaging with the body coil (46). However, while
11 adequate images of ventilation and airspace diffusivity can be generated without one, a calibration
12 scan is recommended to ensure optimal image quality.
13
14
15

16
17 Dissolved-phase imaging demands a more exact flip angle calibration, exact knowledge of the
18 resonant peak frequencies and, for single point methods recommended herein, a precise
19 calibration of sequence timing parameters (47). Typically, calibration scans based on MR
20 spectroscopy include a series of RF excitations on both the gas and dissolved frequencies.
21 Spectra from the dissolved ^{129}Xe signal can be used to calibrate the echo time (TE) parameter
22 when using 1-point Dixon approaches (11) based on the relative phase difference between the
23 RBC and tissue/plasma peaks. Moreover, these spectra can be used to acquire potentially
24 important biomarker information such as RBC chemical shift and global hemodynamics. The gas
25 spectra can be used to calibrate flip angle, α , by fitting peak intensities to a simple model of gas
26 signal decay (neglecting T_1 relaxation).
27
28
29
30
31
32

$$S_i = S_0 \cos(\alpha)^{i-1} + C \quad (1)$$

33
34 In this equation, S_i is the magnitude of the signal intensity resulting from the i th excitation, S_0 is
35 the magnitude of the signal from the first excitation, and C is a noise offset useful for improving fit
36 quality.
37
38
39
40

41 **2.2 Ventilation**

42
43 Ventilation imaging is the simplest, most intuitive, and most widely used application of HP ^{129}Xe
44 MRI (2). This imaging approach provides quantifiable visualization of inhaled gas distribution
45 within the lungs. Conventionally, ventilation images are acquired using 2D slice selective or 3D
46 imaging with Cartesian encoding, which is accomplished with a fast gradient echo or steady state
47 sequence (2,3,16,41,48,49). Using these techniques, 10-24 slices of the lungs are imaged with
48 high in-plane resolution relative to nuclear scintigraphy, SPECT, and PET imaging of ventilation,
49 providing maps of the ventilation distribution throughout the lungs.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 While the current manuscript is primarily focused on imaging protocols rather than analysis, it is
4 necessary to note that ventilation images are most commonly quantified by expressing the
5 percentage of lung voxels exhibiting no signal or low signal intensity, representing non-ventilated
6 or under-ventilated airspaces, which is referred to as the ventilation defect percentage (VDP). A
7 basic definition for VDP can be given as (50):
8
9

$$VDP = \frac{1 - VV}{TLV} \times 100\% \quad (2)$$

10
11
12
13
14 In equation 2, VV is the lung ventilated volume, and total lung volume (TLV) is calculated by
15 segmentation of the thoracic cavity. Ventilation imaging using HP ¹²⁹Xe has shown sensitivity to
16 early lung function decline and disease progression in a wide variety of pulmonary diseases
17 including asthma, COPD, LAM, and CF (14,21,31,51-53). Moreover, it has been implemented
18 using both ³He and ¹²⁹Xe in multi-site trials (54,55), with notable HP ¹²⁹Xe multisite studies that
19 included evaluation of CF (16) and asthma patients (22), as well as recent phase III clinical trials
20 of patients being evaluated for resection and transplant (41,42). Most notably, ventilation imaging
21 will be the initial indication to be approved by the FDA in the USA, which also represents the driver
22 for more than half of referrals received in the clinical setting in the UK to date.
23
24
25
26
27
28

29 **2.3 Alveolar-Airspace Size**

30
31 The diffusive motion of polarized ¹²⁹Xe atoms within the restrictive airspace environment of the
32 lung alveoli and terminal airways can be measured to provide a marker of alveolar-airspace
33 dimensions in the lungs (56). Collisions with the alveolar/acinar walls restrict the diffusive motion
34 of xenon, reducing the apparent diffusion coefficient (ADC) compared free xenon (0.06 cm²/s in
35 pure xenon and 0.14 cm²/s at infinite dilution in air) (57). However, when airspaces are enlarged
36 through normal aging or disease (e.g., emphysema), the diffusive motion of xenon is less
37 restricted, which manifests as a larger measured ADC (25,58,59). Such imaging has proven
38 sensitive to age- and disease-related alterations to the pulmonary microstructure (24-
39 26,29,58,60). Moreover, HP ¹²⁹Xe ADC measurements have been rigorously benchmarked
40 against HP ³He diffusion weighted imaging measurements (26,60,61) that have been validated in
41 comparison to lung tissue histology.
42
43
44
45
46
47
48

49 Alveolar-airspace size imaging is most often performed using a diffusion weighted, 2D slice
50 selective gradient echo sequence with bipolar diffusion gradients (24,26,60,62,63). For
51 applications requiring only ADC, it is common to use two diffusion weightings (b-values), often b
52 = 0, and 12 s/cm² (24,26). ADC is calculated using
53
54
55
56
57
58
59
60

$$S_b = S_0 \exp(-b \cdot ADC) \quad (3)$$

where S_0 is the signal without diffusion weighting and S_b is that for the image acquired with b-value b . To minimize motion sensitivity and ensure similar RF history between images acquired at different b-values, an interleaved approach is employed in which the two b-values are acquired in order (e.g. $b = 0 \text{ s/cm}^2$ followed by $b = 12 \text{ s/cm}^2$) for each line of k-space.

Alternatively, advanced diffusion weighted imaging can be combined with a theoretical model of the pulmonary geometry or a mathematical model of diffusion behavior to calculate lung morphometry parameters (61,64,65); this requires acquiring additional b-values at the expense of longer scan times or reduced spatial resolution. Such diffusion morphometry techniques have been well-validated in animals, humans, and realistic airway geometries (28,29,66-70).

2.4 Gas Exchange

The solubility of ^{129}Xe in tissue/plasma (197 ppm) and RBCs (218 ppm) with distinct chemical shifts makes hyperpolarized ^{129}Xe MRI uniquely capable of characterizing regional gas exchange (4,5).

MR spectroscopy can be used to quantify tissue/plasma uptake and RBC transfer in the whole-lung. This provides measures of RBC chemical shift that are sensitive to blood oxygenation levels (8) while the RBC/TP ratio has demonstrated sensitivity to longitudinal changes in IPF patients (35). Moreover, cardiogenic oscillations in the RBC signal (8) occurring within the breath-hold are sensitive to disease state in IPF and PAH (9,33,71). Alternatively, by acquiring spectra after a variety of uptake times (i.e. acquire spectra with multiple different TRs), gas exchange dynamics can be probed (12). This technique is known as chemical shift saturation recovery (CSSR), which can be fit to a model of gas uptake to extract parameters describing pulmonary structure, including surface-area-to-volume ratio and septal wall thickness (7,19,58,72-77).

It is also possible to quantify regional gas exchange using MR spectroscopic imaging techniques. Techniques implemented for “gas exchange imaging” include the 1-point Dixon method (11), and several multi-echo approaches (10,13,36,78). While multi-echo techniques are experimentally more robust (see Section 4.4), we focus here on 1-Point Dixon imaging based on the body of clinical experience to date. In this technique, gas and dissolved phase signal are simultaneously acquired using 3D radial imaging with an echo time such that RBC and tissue/plasma signal are 90° out of phase (11). This 90° phase separation allows the dissolved phase signals to be separated into their constituent RBC and tissue/plasma images. Combined with the interleaved

1
2
3 gas-phase data, this approach produces images of ventilation, tissue/plasma, and RBC within a
4 single breath hold. These methods have been demonstrated at both 1.5T and 3T and across
5 multiple imaging platforms (47). Moreover, they have been used in a broad range of disease
6 states (33,34,79), and have been shown to predict outcomes (80) and detect therapy response
7 (81,82).
8
9
10

11 **3. IMAGING RECOMMENDATIONS**

12
13
14 In the following section, we provide specific recommendations for xenon dosing, acquisition order,
15 physiologic monitoring, and imaging of the different HP ^{129}Xe MRI contrasts. Recommendations
16 are limited to dosing and imaging, but some discussion of practical considerations such as
17 instrumentation and technical requirements (Supporting Information S1.2) and subject positioning
18 and physiologic monitoring (Supporting Information S1.3) are also provided.
19
20
21

22 **3.1 Xenon Dosing**

23
24 Standardized dosing is essential for generating reproducible signal-to-noise-ratio (SNR) and lung
25 inflation, and thus for obtaining repeatable quantitative imaging biomarkers. The dose is
26 administered by inhalation from a delivery bag that contains HP ^{129}Xe as well as other stable Xe
27 isotopes and buffer gas (nitrogen or helium), which are added to tailor the overall volume for
28 consistent lung inflation. The dose attributes that determine image SNR are threefold — the
29 volume of Xe gas administered, the ^{129}Xe isotopic abundance, and its degree of hyperpolarization
30 (Figure 1). This can be described as the dose equivalent volume (DEV), given by
31
32
33
34
35

$$36 \quad DEV = f_{129} \times P_{129} \times V_{Xe}$$

37
38 where f_{129} is the isotopic fraction of ^{129}Xe , P_{129} is ^{129}Xe nuclear spin polarization, and V_{Xe} is the
39 total volume of xenon gas. Conceptually the DEV represents an equivalent ^{129}Xe volume that is
40 100% isotopically enriched and 100% polarized (83). Xenon gas is typically purchased in naturally
41 abundant (~26% ^{129}Xe) or isotopically enriched mixtures (>80% ^{129}Xe). The use of enriched xenon
42 leads to higher DEV for a given xenon dose volume, which is beneficial for many imaging
43 applications. Naturally abundant xenon ($f_{129} = 26\%$) is a low-cost alternative (~1/10 the cost of
44 enriched xenon) that has proven effective for ventilation imaging assuming sufficiently high P_{129}
45 can be achieved to offset the lower f_{129} (49). The DEV required for a given scan is determined
46 by the desired resolution and SNR requirements of that scan. For example, the DEV used for
47 ventilation imaging in the recent phase III clinical trials was a target of 75 mL, with a minimum
48 allowable value of 50 mL (41,42), which consistently led to ventilation images with SNR of 20-30.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Generally, calibration and ventilation imaging require lower DEV (~75-150 mL), while alveolar-
4 airspace size and gas exchange imaging require higher DEV (>150 mL). The DEV should be set
5 to target an SNR 30-50 in ventilation images, SNR > 15 in alveolar-airspace size images (for all
6 b-values), and SNR > 15 in dissolved phase images.
7
8
9

10 From an operational perspective, the target DEV for a given scan should be achieved with the
11 smallest possible xenon volume since this both reduces cost and the dose constituent that most
12 influences the adverse event (AE) profile. The first study of HP ¹²⁹Xe MRI safety and tolerability
13 administered a total of 3-4 doses of 1-L of pure xenon, and while reporting good safety and
14 tolerability, a very high incidence of transient effects (91%) after each dose, such as dizziness
15 (59%), paresthesia (34%), hypoesthesia (30%), and euphoric mood (30%) (39). While these
16 effects resolved rapidly without intervention (1.6±0.9 min), many subsequent studies have limited
17 the single dose xenon volume to ≤750 mL. A study of safety and tolerability using only 500 mL of
18 xenon reported only 1 event of light-headedness (out of 136 dose administrations), and this
19 resolved within 2 minutes without intervention (40).
20
21
22
23
24
25

26 Beyond the ¹²⁹Xe-dose-related aspects that impact SNR, the level of lung inflation at the time of
27 imaging affects repeatability of quantitative markers of ventilation, alveolar-airspace size, and gas
28 exchange imaging (19,84-86). Lung inflation during HP gas MRI is determined both by the initial
29 inflation state of the lungs prior to xenon inhalation and by the total volume of gas delivered to the
30 subject. To date, the majority of studies have had subjects inhale doses from functional residual
31 capacity (FRC) (1,38,48,59,62,83,87,88), though some have started from residual volume (RV)
32 (58,63). Ultimately, it is unclear whether inhaling from FRC or RV provides better reproducibility
33 of lung inflation. However, given that FRC is a more natural lung volume for subjects and that it
34 has been used in the preponderance of studies, we recommend inhalation from FRC using a
35 standardized coaching pattern (see Supporting Information S1.5).
36
37
38
39
40
41
42

43 Most commonly, the total volume of gas delivered to subjects (usually 1 L) has been held constant
44 for all subjects independent of age and lung size (20,24,31,48,62,83). However, others have
45 tailored total volume based on a subject's total lung capacity (TLC) (16,38) or forced vital capacity
46 (FVC) (10,63). To date, a consensus has yet to be reached regarding best practices for calculating
47 dose volumes. However, because lung volumes vary widely across lung diseases, and HP ¹²⁹Xe
48 MRI biomarkers are known to be affected by lung inflation (89), we suggest tailoring total gas
49 volume to the individual. One relatively straightforward method of doing so is to use 1/6 of the
50 subject's calculated TLC or 20% of their measured FVC. This dose volume is roughly twice the
51 subject's tidal volume, making it comfortable for inhalation. Moreover, lung volumes can be readily
52
53
54
55
56
57
58
59
60

1
2
3 obtained at bedside using spirometry in advance of imaging or can be estimated based on race,
4 sex, age, and height (90,91), for example using the prediction tool provided by the Global Lung
5 Function Initiative (<http://gli-calculator.ersnet.org/index.html>).
6
7

8 Once polarized, xenon should be dispensed into a Tedlar (polyvinyl fluoride) dose bag for delivery
9 to the subject. Tedlar is used because it is inert and induces minimal relaxation of hyperpolarized
10 ^{129}Xe (43,92). The bag should be sized close to the desired dose volume, because partially filled
11 bags will experience faster signal relaxation (92).
12
13
14

15 The choice of buffer gas should also be standardized within an individual trial due to possible
16 differences in dose weight, density, diffusivity, and viscosity, which could affect ventilation
17 distributions and ADC measurements (20,22). The buffer gas should be physiologically inert;
18 previously, both nitrogen (N_2) (16,64) and helium (^4He) (29,60) have been used to balance xenon
19 gas to the desired dosage volume. Because xenon is heavier than air, helium has the advantage
20 of bringing the mean molecular weight of the dose closer to room air, which allows higher relative
21 Brownian diffusivity and more temporally efficient measurement of alveolar and airway
22 microstructures (60). However, current commercial polarization technology and the relatively high
23 cost of ^4He (~ a factor of 10 greater cost) supports the use of N_2 . Regardless of buffer gas choice,
24 every effort should be made to remove all oxygen from the dose bag; being paramagnetic oxygen
25 is the most potent driver of ^{129}Xe relaxation.
26
27
28
29
30
31
32

33 **3.2 Scan Acquisition Order**

34
35 Once hyperpolarized xenon is dispensed into a Tedlar bag, it should be kept within a static
36 magnetic field of >0.5 mT (>5 Gauss) to maintain its polarization until administration.
37 Hyperpolarized signal decays by longitudinal relaxation (at 2 mT, $T_1 \sim 1.5$ -2 hrs), and therefore
38 ^{129}Xe polarization should be measured using a polarimeter (see Supporting Information S1.2)
39 within 5 min of administration. In settings where the distance between polarizer and MRI is large,
40 or where polarization performance is insufficient to support “on demand” gas preparation, it is
41 preferable to perform the more “signal-starved” scans (e.g. gas exchange) with freshly dispensed
42 doses, while others (e.g. calibration, or static ventilation) can use those that have been allowed
43 to relax for some time. Because the time required to prepare a dose of HP ^{129}Xe varies with the
44 production rate of the polarizer ($\sim 1 - 5$ L/hr), it is often not feasible to prepare an additional dose
45 quickly if images are unacceptable (subject moves, exhales, etc.). Thus, for particularly
46 challenging patients in whom there is risk of poor compliance, the primary endpoint scan may be
47 acquired with the first xenon dose to allow for additional re-scans. If ^{129}Xe MRI is being performed
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in conjunction with gadolinium dynamic contrast enhanced ^1H perfusion MRI, ^{129}Xe MRI should
4 be completed before IV contrast administration.
5

6 7 **3.3 Dissolved Phase Spectroscopy/Flip Angle, Center Frequency, and Timing Calibration** 8

9 For calibration, we recommend a dedicated scan that measures flip angle and characterizes the
10 dissolved-phase ^{129}Xe signal while also providing a maximally accurate measure of center
11 frequency. Here, we recommend a non-localized, spectroscopic acquisition that can further be
12 analyzed for several physiologically-relevant parameters, including a careful measure of RBC
13 chemical shift (as a measure of capillary blood oxygenation) (8) as well as cardiogenic oscillations
14 in RBC amplitude (9).
15
16
17
18

19 This calibration sequence consists of 500 free induction decay (FID) acquisitions with RF
20 excitation centered at the dissolved ^{129}Xe frequency followed by 20 at the gaseous frequency.
21 These enable calculating the gas and dissolved phase frequencies, while determining the timing
22 parameters and flip angle for each subject. In addition to flip angle, acquisition TR is the strongest
23 determinant of the relative ratio of RBC to tissue/plasma signal and has been set to 15 ms to
24 match the gas exchange acquisition discussed later (11,47). This TR does sacrifice some spectral
25 resolution, given the large spectral width of the RBC and tissue/plasma peaks, does not
26 compromise their measurement. Recommended parameters are shown in Table 2.
27
28
29
30
31

32 This calibration sequence should be analyzed (Figure 2) during the imaging session and prior to
33 prescribing the subsequent imaging scans. In practice, calibration data are analyzed immediately
34 following the scan, either online on the scanner, or after exporting into an offline processing
35 program. It is useful to use time domain fitting to analyze gas and dissolved phase spectra from
36 the calibration scan, which provides high quality fitting even given the relatively coarse spectral
37 resolution (93). The total time for calibration analysis typically is 1-3 minutes, depending on
38 specific calibration software used and computing power.
39
40
41
42
43

44 The first 100 dissolved FIDs should be discarded, as they contain ^{129}Xe signal that has
45 accumulated during inhalation in the larger vasculature “downstream” of the pulmonary capillary
46 bed. This number of discarded FIDs could be reduced by using a smaller number (~10) of dummy
47 scans with a high flip angle prior to signal acquisition with a 20° flip angle, but, for simplicity, our
48 current recommendation uses this more basic approach. The 67 following FIDs (i.e. FID 101-168)
49 should be averaged and fit to obtain the ratio of RBC signal to tissue/plasma signal and to
50 determine the TE at which RBC and tissue/plasma are 90° out of phase (TE_{90}). Such averaging
51
52
53
54
55
56
57
58
59
60

encompasses approximately one full cardiac cycle to account for cardiogenic changes to RBC signal amplitude or chemical shift (9). From this calibration spectrum, TE_{90} can be calculated as

$$TE_{90} = TE + \frac{90 - (Phase(RBC) - Phase(tissue/plasma))}{360 \times (Frequency(RBC) - Frequency(tissue/plasma))}. \quad (4)$$

where TE is the echo time used in the calibration scan (0.45 or 0.8 ms for 3T or 1.5T). For imaging at 3T (1.5T), TE_{90} should be in the range 0.45-0.50 (0.8-1.1) ms. If calibration analysis results fall outside of this range, we suggest $TE_{90} = 0.47$ (1.0) ms.

A generic Matlab (Mathworks, Natick, MA) function has been created and made available for this calibration analysis (https://github.com/pniedbalski3/Xenon_Generic_Calibration).

The remaining dissolved FIDs can optionally be used at a later time to analyze RBC oscillation amplitude and frequency dynamics (9). FIDs 501-520 contain the gas phase signal and should be used to establish the in vivo gas-phase center frequency and to calibrate the true applied flip angle using Equation 1.

3.4 Ventilation Imaging

To date, most studies reporting ventilation imaging have employed 2D slice selective imaging with fast gradient echo encoding. Such Cartesian encoding of k-space typically requires the least specific sequence programming on all scanner platforms and does not require sophisticated off-line reconstruction or corrections. As such, we recommend that ventilation imaging be performed using a 2D RF-spoiled gradient echo imaging sequence. Proposed imaging parameters are shown in Table 3, with representative images in Figure 3. The proposed resolution (4x4 mm² in-plane) was selected to adequately capture ventilation details, while being sufficiently conservative to ensure high image SNR and quality, even without a dedicated calibration scan.

For effective quantification of ventilation defect percentage most analysis techniques employ an anatomical image acquired using an ¹H coil (often the body coil) immediately before or after the ventilation scan (50,94). This should be acquired during a breath-hold of room air that is volume-matched to the xenon dose and using the same breath hold coaching. This scan should reveal the outline of the thoracic cavity for masking and major blood vessels so that they can be segmented out of the mask. It can also be beneficial to minimize susceptibility artifacts from the ribs which can be present in a GRE sequence, although improved segmentation algorithms mitigate this requirement. Because it is robust to susceptibility artifacts from the ribs, we recommend using a RARE sequence (Rapid Imaging with Relaxation Enhancement (95)) with the suggested parameters in Table 4 and example images in Figure 4.

3.5 Alveolar-Airspace Size Imaging

For basic calculation of the ADC, images are often acquired with only two different levels of diffusion weighting (b-values). If subsequent analysis to perform diffusion morphometry is desired, additional b-values must be acquired. However, this can be challenging due to the time constraints of a 16 s breath-hold (see Section 4.3), and acceleration strategies such as compressed sensing may be needed (64,96). The current recommendations for diffusion-weighted imaging (Table 5) include parameters for either a 2 b-value ADC acquisition or a multiple (4) b-value diffusion morphometry approach with compressed sensing. Example images acquired using these parameters are shown in Figure 5.

The recommended ^{129}Xe diffusion time of 8.5 ms is optimized to probe a diffusion regime that is similar to that explored for ^3He diffusion/ADC imaging, and allows comparable diffusion morphometry metrics to be derived from ^3He and ^{129}Xe (64). This could facilitate retrospective comparisons with previously acquired ^3He diffusion imaging data, while using a diffusion time applicable for diffusion morphometry with both cylinder and stretched exponential models (61).

We note that, while we provide a recommendation for vendor-specific sequence type, bipolar diffusion sensitizing gradients will need to be applied prior to the readout. Furthermore, the transient and non-recoverable nature of the hyperpolarized ^{129}Xe signal requires that every b-value be acquired for a given phase encoding line prior to the next and every phase encoding line for a given slice be acquired prior to moving onto the next slice. Careful attention should be given to this ordering, as some product sequences may use some other non-suitable looping order.

3.6 Gas Exchange Imaging

In 1-point Dixon imaging, gas and dissolved xenon are simultaneously imaged using an interleaved 3D radial imaging sequence to overcome the very short T_2^* of dissolved xenon. The echo time is set such that RBC and tissue/plasma signals are 90° out of phase at the beginning of the imaging readout. After image reconstruction, a phase shift is applied such that the RBC and tissue/plasma signals are shifted to be contained within the real and imaginary channels of the dissolved image. Recommended parameters for 1-point Dixon Imaging are provided in Table 6, and a conceptual sequence diagram and representative images are shown in Figure 6.

As with ventilation imaging, an anatomic scan should be acquired immediately before or after the xenon gas exchange scan and its geometry should be as closely matched to the xenon scan as possible. Recommended parameters are shown in Table 7.

3.7 Exporting Images and Image Analysis

After imaging is complete, images must be reconstructed and/or exported from the scanner for analysis and quantification. For the current recommendations, ventilation images can be effectively reconstructed using vendor reconstruction tools on the scanner. Such images should be exported in a DICOM format using the minimum level of interpolation allowed. However, images of gas exchange and alveolar airspace size may require off-line reconstruction so that proper diffusion analysis and separation of dissolved and gas images and subsequently RBC and tissue/plasma images can be consistently achieved. These reconstruction methods are outside the scope of this position paper, but readers are directed to the work of Chan et al. (61,64) for alveolar airspace size analysis and Kaushik et al. (11) and Wang et al. (47,79) for reconstruction and analysis of gas exchange imaging using the 1-point Dixon method.

There is currently significant discussion within the hyperpolarized ^{129}Xe MRI community regarding best practices for image analysis, including bias field correction, VDP calculation (3,14,50,97-99), ADC calculation (61,65,70,100), and gas exchange quantification (13,79). While these analyses are essential to the HP ^{129}Xe MRI process and must be standardized for any subsequent trial, they are outside the scope of this position paper. Our hope is to address such topics in a future position paper to facilitate site-to-site analysis standardization.

4. CHALLENGES AND AREAS FOR DEVELOPMENT

To deploy the wide variety of regional lung structure and function biomarkers provided by hyperpolarized ^{129}Xe MRI as an endpoint in multi-site clinical trials, requires standardized imaging sequences. However, this must be done while recognizing the ample room for further development and optimization of the various imaging techniques. Many of the more recent advances in HP ^{129}Xe MRI methodology provide improved imaging efficiency or additional biomarkers but may currently be overly challenging to widely implement due to hardware, pulse programming, or analysis considerations across vendors and sites. In the following sections, we detail some of the needed developments to HP ^{129}Xe MRI that will be necessary to improve upon the current recommendations provided.

4.1 Shimming

MRI vendor methods for shimming use ^1H signal to improve magnetic field homogeneity. However, minimal ^1H signal originates from within the lungs, which renders these methods largely ineffective for hyperpolarized gas imaging. Our recommendation is to use default (non-patient-

1
2
3 specific) shim settings for hyperpolarized gas imaging. However, the effect of shimming on image
4 quality and quantitative metrics in HP ^{129}Xe MRI is not well studied, and future work may
5 demonstrate that more attention is required in shim settings (101).
6
7

8 **4.2 Ventilation Imaging**

9

10 The primary motivations for improvement to ventilation imaging are higher SNR, faster image
11 acquisition, improved quantitative markers, and 3D isotropic image resolution. To that end, steady
12 state free precession (SSFP) imaging, spiral encoding, compressed sensing, 3D imaging, or
13 some combination of these are among the more promising methods that may ultimately become
14 standard for ventilation imaging. SSFP imaging has proven to provide high-SNR ventilation
15 images (49,102). It has been most heavily used for imaging at 1.5T, as there is an increase in off-
16 resonance-related banding artifacts when imaging at 3T. “Stack of spirals” imaging has enabled
17 full lung coverage in 1-2 s (98,103-105), which mitigates concerns of subjects exhaling early,
18 particularly in those with severe lung disease. Furthermore, such rapid encoding—which can also
19 be achieved via compressed sensing techniques (106)—enables both ventilation and ^1H
20 anatomical images to be acquired within the same breath, thereby improving image registration
21 and quantitative analysis (107). 3D imaging has several potential advantages, including improved
22 SNR and spatial contiguity of data (108), but is more prone to motion artifacts from respiratory
23 and cardiac motion. Such artifacts can be mitigated through the use of methods that sample k-
24 space from the center-outward, such as radial or spiral imaging (83,109). Moreover, these
25 techniques are robust to undersampling, which mitigates the concerns of early exhalation. 3D
26 radial and spiral sequences are not typically as fast as slice-selective spirals, but allow improved
27 slice resolution and can provide quantitative corrections for signal depletion (110,111).
28
29
30
31
32
33
34
35
36
37
38
39

40 The primary downside of these novel techniques at present for clinical trials is that each requires
41 significant pulse programming and image reconstruction, which is difficult to standardize between
42 sites. Currently, none of the major MRI vendors provide product support for the required spiral or
43 radial imaging sequences as clinical products. Providing multi-platform, standardized tools for
44 fast, quantitative, and high-resolution imaging will be essential to replace fast gradient echo as
45 the standard for ventilation imaging.
46
47
48
49

50 An additional area for improvement is the true quantification of ventilation in ^{129}Xe images. While
51 VDP has shown high sensitivity to disease, ventilation imaging fails to provide a traditional
52 physiologic measure of ventilation such as true ventilation (in L/min) or specific ventilation.
53 Approaches for quantifying fractional ventilation have employed multiple breath imaging
54
55
56
57
58
59
60

1
2
3 techniques (112,113). This presents the requirement of coaching subjects in a multi-breath
4 maneuver, which limits the widespread use of these techniques. A single-breath technique for
5 quantifying regional ventilation in the context of traditional measurements would present a
6 significant advance to the field.
7
8
9

10 While it is somewhat outside of the scope of the current manuscript, it should be noted that a
11 significant open question in ventilation imaging is how to account for B1 or receiver-related
12 inhomogeneity bias in ventilation images. The presence of low-frequency signal intensity
13 modulation can have a significant impact on quantitative metrics acquired from images. This is
14 currently managed using N4ITK (114) bias-field correction, but this technique requires
15 standardization, as different input parameters can lead to different values for VDP. Moreover,
16 overly aggressive bias-field corrections can obscure physiological variations in the HP ^{129}Xe
17 signal. Other, protocol-dependent methods enable the mapping of signal decay (110,115), which
18 could lead toward a “ground truth” map of bias field, enabling a more well-standardized correction.
19 A standardized method of bias-field correction is essential to multi-site harmonization of
20 ventilation imaging analysis.
21
22
23
24
25
26
27

28 **4.3 Alveolar-Airspace Size Imaging**

29
30 For alveolar-airspace size imaging, the main targets for improvement are fast acquisitions, optimal
31 b-value settings, and standardized analysis. Because multiple b-value images are required to
32 map ADC, this imaging method typically requires a longer breath hold or larger voxel sizes than
33 ventilation imaging. Increases in encoding efficiency, such as using spiral trajectories or a
34 standardized compressed sensing method, would be highly beneficial to alveolar-airspace size
35 imaging (61,62,64,96).
36
37
38
39

40 Additionally, analysis should be standardized. Basic mapping of ADC is relatively straightforward
41 using Equation 3, but more advanced diffusion morphometry analysis requires multiple images
42 with different diffusion weighting. There are two established methods of diffusion morphometry
43 analysis, and it is not currently agreed upon which method is preferable. One method, pioneered
44 at Washington University, uses a cylindrical model of acinar geometry to estimate alveolar-duct
45 and alveolar dimensions (65). The other, developed at the University of Sheffield, uses a stretched
46 exponential model to characterize pulmonary morphometry (100). Importantly, both models can
47 be used on the same set of diffusion weighted images provided that the diffusion time (Δ) is set
48 to ensure that images are acquired in the proper diffusion regime (64,65). Each method has
49 shown utility and has been validated against conventional histology (70,116). For future multi-site
50
51
52
53
54
55
56
57
58
59
60

1
2
3 studies that involve diffusion morphometry (not simple ADC), a consensus will need to be reached
4 on which model is preferable.
5

6 7 **4.4. Gas Exchange Imaging** 8

9 Gas exchange imaging, as the newest and most complicated method of hyperpolarized ^{129}Xe
10 MRI, has the most room for development. Currently, imaging using the 1-point Dixon technique
11 is the most broadly implemented method for regional quantification of RBC and tissue/plasma
12 signal due to its relative simplicity and robustness to short T_2^* signal decay. However, there are
13 substantial limitations of the technique that need to be addressed. These include the high degree
14 of undersampling, excitation pulse design, disregard of local phase variations, and chemical-shift-
15 induced phase evolution during the radial read-out.
16
17
18
19

20
21 For the most commonly used radial 1-point Dixon method, pulmonary MR spectroscopic imaging
22 is challenged by the need to acquire images within a breathhold. Spectroscopic imaging requires
23 sampling of both gas and dissolved signals with adequate delay time for gas to diffuse into the
24 tissue/plasma and RBC compartments (117), leading to images being acquired with ~15% of the
25 radial arms required for 100% Nyquist sampling. Radial imaging in this setting is particularly
26 robust to undersampling but can lead to blurring and image artifacts. Spiral k-space trajectories,
27 which are very useful for improving the efficiency of gas-phase imaging ($T_2^* > 20$ ms) (118), are
28 of limited use for 3D imaging of the dissolved phase where transverse signal decays more rapidly
29 ($T_2^* = 1-2$ ms) (36,47,119). Sampling can be improved by using 2D projection imaging (78,120),
30 but this sacrifices the 3D information content of 1-point-Dixon imaging. Rather than 2D imaging,
31 3D imaging with coarser resolution has also been implemented, which likewise improves the
32 sampling percentage of images (10,13). An alternative approach to increasing sampling
33 percentage is to reduce the repetition time of scans alongside a corresponding decrease to
34 applied RF flip angle (117). In doing so, more radial projections can be sampled while retaining
35 similar magnetization dissolved in red blood cells and tissue/plasma. Ultimately, improvements to
36 the sampling percentage of 1-point Dixon imaging would significantly improve image quality and
37 real resolution.
38
39
40
41
42
43
44
45
46
47

48 Excitation pulse design plays a significant role in the quantitative metrics achieved from images.
49 The recommended RF pulse (1-lobed(3-lobed) windowed sinc for 3T(1.5T)) has a narrow
50 frequency profile to avoid gas excitation, but when centered on the RBC resonance can yield a
51 reduced flip angle at the tissue/plasma resonance. This unequal excitation can have a significant
52 impact on standard imaging markers, such as the RBC/TP ratio. Moreover, even with this narrow
53
54
55
56
57
58
59
60

1
2
3 excitation profile, there is often some excitation of gas signal. Gas signal generated by imperfectly
4 selective, dissolved-phase resonance excitation can deleteriously impact quantitative analysis of
5 dissolved phase images. Several methods could be used to mitigate this issue. A more optimal
6 RF pulse could reduce the intensity of off resonance gas-phase excitation. Rather than changing
7 the excitation pulse, gas contamination can also be mitigated using pulse sequence or analysis
8 methods. One such method is to adapt the pulse sequence to acquire a second set of dissolved
9 and gas phase images at longer echo time. Because the T_2^* of dissolved phase ^{129}Xe is very short
10 ($\sim 1(2)$ ms at $3T(1.5T)$) (36,47,119), images at longer echo time will contain only gas-phase signal,
11 providing a simple measurement of the degree of gas phase contamination (121). Alternatively,
12 gas contamination can be removed through the use of multi-echo sampling techniques (13). Gas
13 contamination can also be removed in analysis by estimating the gas contamination based on the
14 intensity and phase of the gas-phase signal (122). It is unclear which of these methods provides
15 the most robust and easily standardized gas contamination removal. Ultimately, improved pulse
16 shape or pulse sequence design, implemented in a standardized, multi-platform manner, will
17 significantly improve the ability to differentiate gas-phase and dissolved-phase signal in gas
18 exchange imaging.

19
20
21
22
23
24
25
26
27
28
29 The separation of RBC and tissue/plasma images in 1-point Dixon imaging is accomplished by
30 acquiring images at the dissolved frequencies at TE_{90} , where there is a 90° phase separation
31 between the two at the beginning of the readout. As a result, they are only perfectly separated at
32 the center of k-space, which encodes image contrast (i.e. signal intensity). However, the phase
33 separation between RBC and tissue/plasma signal continues to evolve throughout the radial
34 readout, which likely causes blurring to the fine detail of images. The extent to which this impacts
35 the derived quantitative imaging metrics not been rigorously examined. Other methods that have
36 demonstrated the ability to separate RBC and tissue/plasma signals in the context of 3D imaging
37 are 3D CSI (123) and multi-point imaging methods (10,13). Both of these methods are likely to
38 provide improved separation of RBC and tissue/plasma signal over 1-point Dixon imaging, but
39 neither of these methods have been as well-published or broadly disseminated as the 1-point
40 Dixon approach. 3D chemical shift imaging can generate full spectra for each voxel and thus
41 generate T_2^* images for each slice and images of the relative chemical shift position of each peak
42 in the same acquisition (124). It is slower than 1-point Dixon and thus requires slightly coarser
43 resolution, but recent improvements suggest the ability to get similar resolution to 1 Point Dixon
44 imaging within a 9 s breath-hold. This CSI method showed the ability to detect regional physiologic
45 lung changes in disease (124). 3D imaging using Multi-point imaging has been reported at 1.5T
46 (10,13,36), but its use at 3T has not been published. Implementations at 1.5T used maximum TEs
47
48
49
50
51
52
53
54
55
56
57

1
2
3 of 3.98 ms (10), 3.1 ms (36), and 2.6 ms (13), all of which are considerably beyond the dissolved
4 phase T_2^* at 3T ($T_2^* \sim 1$ ms). Thus, further work is necessary to demonstrate and standardize
5 multi-point-based 3D gas exchange imaging at 3T, the field strength of most commercial multi-
6 nuclear MRI scanners.
7
8

9
10 Finally, the 1-point Dixon method of imaging gas exchange provides only a single static
11 “snapshot” of the gas uptake process, which is inherently dynamic. Conversely, there are a
12 number of methods that provide improved temporal analysis of gas exchange at the sacrifice of
13 the comparatively high spatial resolution provided by 1-point Dixon imaging (7,74,120,125).
14 Methods that are able to achieve temporal sampling of gas exchange while maintaining sufficient
15 spatial resolution are needed to fully quantify the complex dynamics of the gas exchange process.
16
17
18

19 20 **4.5 Pediatric Imaging**

21
22 We have provided our recommendations specifically for adult imaging. Each of these protocols
23 can be used for imaging pediatric subjects (with an active, multi-site study in pediatric CF currently
24 ongoing), although small changes may be necessary based upon the size range and patient
25 populations. Pediatric imaging poses several challenges, including increased likelihood of breath
26 hold non-compliance, smaller anatomy, and difference in disease pathophysiology. As such,
27 protocols may need to be adapted to change dosage volume, increase imaging resolution (due
28 to decreased field of view), or shorten breath holds (14-16,38,51,113,126).
29
30
31
32
33

34 **CONCLUSIONS**

35
36 Researchers are continuously developing and improving methods of imaging hyperpolarized
37 ^{129}Xe to quantify pulmonary structure and function. However, this continuous state of development
38 can hinder the use of hyperpolarized ^{129}Xe MRI in clinical trials, as there are currently no published
39 standard imaging sequences for multi-site studies. In this position paper, we have presented
40 recommended imaging protocols from the ^{129}Xe MRI Clinical Trials Consortium for HP ^{129}Xe MRI
41 in adults, including calibration, ventilation, diffusion, and gas exchange scans. These
42 recommended protocols are based on well-validated methods and have demonstrated ability to
43 quantify aberrant lung structure and function across vendors and sites. At the same time,
44 parameter settings are sufficiently generic and conservative that any site enabled for HP ^{129}Xe
45 MRI will be capable of reproducing the parameters specified herein and producing high quality
46 images. While seeking to be widely applicable, these recommended protocols necessarily omit
47 some of the highly effective sequences used by some HP ^{129}Xe MRI sites. It is our hope that such
48 novel techniques will be further standardized using a procedure similar to that used by the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Quantitative Imaging Biomarkers Alliance (QIBA). Namely, new sequences will be discussed
4 within the ^{129}Xe MRI Clinical Trials Consortium, with opportunities for comments from those within
5 the field. Then, proposed new methods will require technical confirmation by being implemented
6 at multiple new sites and across vendors. As a final step, methods will require clinical confirmation,
7 where they are used successfully in a multi-site clinical trial. Ultimately, we hope that this
8 dissemination of current protocols and roadmap for next steps will accelerate the adoption of HP
9 ^{129}Xe MRI as a modality for multi-site trials and for clinical implementation.
10
11
12
13

14 REFERENCES

- 15
16
17 1. Roos JE, McAdams HP, Kaushik SS, Driehuys B. Hyperpolarized Gas MR Imaging:
18 Technique and Applications. *Magn Reson Imaging Clin N Am* 2015;23(2):217-229.
- 19 2. Mugler JP, Altes TA. Hyperpolarized ^{129}Xe MRI of the human lung. *J Magn Reson*
20 *Imaging* 2013;37(2):313-331.
- 21 3. He M, Driehuys B, Que LG, Huang YCT. Using Hyperpolarized Xe-129 MRI to Quantify
22 the Pulmonary Ventilation Distribution. *Acad Radiol* 2016;23(12):1521-1531.
- 23 4. Driehuys B, Cofer GP, Pollaro J, Mackel JB, Hedlund LW, Johnson GA. Imaging
24 alveolar-capillary gas transfer using hyperpolarized Xe-129 MRI. *Proc Natl Acad Sci*
25 *USA* 2006;103(48):18278-18283.
- 26 5. Cleveland ZI, Cofer GP, Metz G, Beaver D, Nouls J, Kaushik SS, Kraft M, Wolber J,
27 Kelly KT, McAdams HP, Driehuys B. Hyperpolarized Xe-129 MR Imaging of Alveolar
28 Gas Uptake in Humans. *PLoS One* 2010;5(8):e12192.
- 29 6. Wang Z, Rankine L, Bier EA, Mummy D, Lu J, Church A, Tighe RM, Swaminathan A,
30 Huang Y-CT, Que LG, Mammarrappallil JG, Rajagopal S, Driehuys B. Using
31 hyperpolarized ^{129}Xe gas-exchange MRI to model the regional airspace, membrane,
32 and capillary contributions to diffusing capacity. *J Appl Physiol* 2021;130(5):1398-1409.
- 33 7. Stewart NJ, Leung G, Norquay G, Marshall H, Parra-Robles J, Murphy PS, Schulte RF,
34 Elliot C, Condliffe R, Griffiths PD, Kiely DG, Whyte MK, Wolber J, Wild JM. Experimental
35 validation of the hyperpolarized Xe-129 chemical shift saturation recovery technique in
36 healthy volunteers and subjects with interstitial lung disease. *Magn Reson Med*
37 2015;74(1):196-207.
- 38 8. Norquay G, Leung G, Stewart NJ, Wolber J, Wild JM. ^{129}Xe chemical shift in human
39 blood and pulmonary blood oxygenation measurement in humans using hyperpolarized
40 ^{129}Xe NMR. *Magn Reson Med* 2017;77(4):1399-1408.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 9. Bier EA, Robertson SH, Schrank GM, Rackley C, Mammarappallil JG, Rajagopal S,
4 McAdams HP, Driehuys B. A protocol for quantifying cardiogenic oscillations in dynamic
5 (129) Xe gas exchange spectroscopy: The effects of idiopathic pulmonary fibrosis. *NMR*
6 *Biomed* 2019;32(1):e4029-e4029.
- 7
8
9 10. Qing K, Ruppert K, Jiang Y, Mata JF, Miller GW, Shim YM, Wang C, Ruset IC, Hersman
10 FW, Altes TA, Mugler JP. Regional Mapping of Gas Uptake by Blood and Tissue in the
11 Human Lung Using Hyperpolarized Xenon-129 MRI. *J Magn Reson Imaging*
12 2014;39(2):346–359.
- 13
14
15 11. Kaushik SS, Robertson SH, Freeman MS, He M, Kelly KT, Roos JE, Rackley CR, Foster
16 WM, McAdams HP, Driehuys B. Single-Breath Clinical Imaging of Hyperpolarized Xe-
17 129 in the Airways, Barrier, and Red Blood Cells Using an Interleaved 3D Radial 1-
18 Point Dixon Acquisition. *Magn Reson Med* 2016;75(4):1434-1443.
- 19
20
21 12. Norquay G, Leung G, Stewart NJ, Tozer GM, Wolber J, Wild JM. Relaxation and
22 exchange dynamics of hyperpolarized 129Xe in human blood. *Magn Reson Med*
23 2015;74(2):303-311.
- 24
25
26 13. Collier GJ, Eaden JA, Hughes PJC, Bianchi SM, Stewart NJ, Weatherley ND, Norquay
27 G, Schulte RF, Wild JM. Dissolved 129Xe lung MRI with four-echo 3D radial
28 spectroscopic imaging: Quantification of regional gas transfer in idiopathic pulmonary
29 fibrosis. *Magn Reson Med* 2021;85(5):2622-2633.
- 30
31
32 14. Thomen RP, Walkup LL, Roach DJ, Cleveland ZI, Clancy JP, Woods JC. Hyperpolarized
33 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients. *J Cyst*
34 *Fibros* 2017;16(2):275-282.
- 35
36
37 15. Kanhere N, Couch MJ, Kowalik K, Zanette B, Rayment JH, Manson D, Subbarao P,
38 Ratjen F, Santyr G. Correlation of Lung Clearance Index with Hyperpolarized 129Xe
39 Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. *Am J Respir Crit*
40 *Care Med* 2017;196(8):1073-1075.
- 41
42
43 16. Couch MJ, Thomen R, Kanhere N, Hu R, Ratjen F, Woods J, Santyr G. A two-center
44 analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: Potential as
45 a biomarker for multi-site trials. *J Cyst Fibros* 2019;18(5):728-733.
- 46
47
48 17. Woods JC, Wild JM, Wielpütz MO, Clancy JP, Hatabu H, Kauczor H-U, van Beek EJR,
49 Altes TA. Current state of the art MRI for the longitudinal assessment of cystic fibrosis. *J*
50 *Magn Reson Imaging* 2020;52(5):1306-1320.
- 51
52
53
54
55
56
57
58
59
60

- 1
2
3 18. Smith LJ, Horsley A, Bray J, Hughes PJC, Biancardi A, Norquay G, Wildman M, West N,
4 Marshall H, Wild JM. The assessment of short and long term changes in lung function in
5 CF using ^{129}Xe MRI. *Eur Respir J* 2020;56(6):2000441.
6
7
- 8 19. Qing K, Mugler JP, 3rd, Altes TA, Jiang Y, Mata JF, Miller GW, Ruset IC, Hersman FW,
9 Ruppert K. Assessment of lung function in asthma and COPD using hyperpolarized
10 ^{129}Xe chemical shift saturation recovery spectroscopy and dissolved-phase MRI. *NMR*
11 *Biomed* 2014;27(12):1490-1501.
12
13
- 14 20. Svenningsen S, Kirby M, Starr D, Leary D, Wheatley A, Maksym GN, McCormack DG,
15 Parraga G. Hyperpolarized ^3He and ^{129}Xe MRI: Differences in asthma before
16 bronchodilation. *J Magn Reson Imaging* 2013;38(6):1521-1530.
17
18
- 19 21. Ebner L, He M, Virgincar RS, Heacock T, Kaushik SS, Freemann MS, McAdams HP,
20 Kraft M, Driehuys B. Hyperpolarized (^{129}Xe) Xenon Magnetic Resonance Imaging to
21 Quantify Regional Ventilation Differences in Mild to Moderate Asthma A Prospective
22 Comparison Between Semiautomated Ventilation Defect Percentage Calculation and
23 Pulmonary Function Tests. *Invest Radiol* 2017;52(2):120-127.
24
25
- 26 22. Svenningsen S, McIntosh M, Ouriadov A, Matheson AM, Konyer NB, Eddy RL,
27 McCormack DG, Noseworthy MD, Nair P, Parraga G. Reproducibility of Hyperpolarized
28 ^{129}Xe MRI Ventilation Defect Percent in Severe Asthma to Evaluate Clinical Trial
29 Feasibility. *Acad Radiol* 2020.
30
31
- 32 23. Qing K, Tustison NJ, Mugler JP, Mata JF, Lin Z, Zhao L, Wang D, Feng X, Shin JY,
33 Callahan SJ, Bergman MP, Ruppert K, Altes TA, Cassani JM, Shim YM. Probing
34 Changes in Lung Physiology in COPD Using CT, Perfusion MRI, and Hyperpolarized
35 Xenon-129 MRI. *Acad Radiol* 2019;26(3):326-334.
36
37
- 38 24. Kaushik SS, Cleveland ZI, Cofer GP, Metz G, Beaver D, Nouls J, Kraft M, Wolber J,
39 Kelly KT, Auffermann W, McAdams HP, Driehuys B. Diffusion Weighted Imaging of
40 Hyperpolarized ^{129}Xe in Patients with Chronic Obstructive Pulmonary Disease. *Magn*
41 *Reson Med* 2011;65(4):1154–1165.
42
43
- 44 25. Thomen RP, Quirk JD, Roach D, Egan-Rojas T, Ruppert K, Yusen RD, Altes TA,
45 Yablonskiy DA, Woods JC. Direct comparison of Xe-129 diffusion measurements with
46 quantitative histology in human lungs. *Magn Reson Med* 2017;77(1):265-272.
47
48
- 49 26. Kirby M, Svenningsen S, Owrangi A, Wheatley A, Farag A, Ouriadov A, Santyr GE,
50 Etemad-Rezai R, Coxson HO, McCormack DG, Parraga G. Hyperpolarized He-3 and
51 Xe-129 MR Imaging in Healthy Volunteers and Patients with Chronic Obstructive
52 Pulmonary Disease. *Radiology* 2012;265(2):600-610.
53
54
55
56
57

- 1
- 2
- 3 27. Dregely I, Mugler JP, Ruset IC, Altes TA, Mata JF, Miller GW, Ketel J, Ketel S,
- 4 Distelbrink J, Hersman FW, Ruppert K. Hyperpolarized Xenon-129 Gas-Exchange
- 5 Imaging of Lung Microstructure: First Case Studies in Subjects With Obstructive Lung
- 6 Disease. *J Magn Reson Imaging* 2011;33(5):1052-1062.
- 7
- 8
- 9 28. Ouriadov A, Farag A, Kirby M, McCormack DG, Parraga G, Santyr GE. Lung
- 10 morphometry using hyperpolarized 129Xe apparent diffusion coefficient anisotropy in
- 11 chronic obstructive pulmonary disease. *Magn Reson Med* 2013;70(6):1699-1706.
- 12
- 13
- 14 29. Ouriadov A, Farag A, Kirby M, McCormack DG, Parraga G, Santyr GE. Pulmonary
- 15 hyperpolarized 129Xe morphometry for mapping xenon gas concentrations and alveolar
- 16 oxygen partial pressure: Proof-of-concept demonstration in healthy and COPD subjects.
- 17 *Magn Reson Med* 2015;74(6):1726-1732.
- 18
- 19
- 20 30. Matin TN, Rahman N, Nickol AH, Chen M, Xu XJ, Stewart NJ, Doel T, Grau V, Wild JM,
- 21 Gleeson FV. Chronic Obstructive Pulmonary Disease: Lobar Analysis with
- 22 Hyperpolarized Xe-129 MR Imaging. *Radiology* 2017;282(3):857-868.
- 23
- 24
- 25 31. Walkup LL, Roach DJ, Hall CS, Gupta N, Thomen RP, Cleveland ZI, McCormack FX,
- 26 Woods JC. Cyst Ventilation Heterogeneity and Alveolar Airspace Dilation as Early
- 27 Disease Markers in Lymphangiomyomatosis. *Ann Am Thorac Soc* 2019;16(8):1008-
- 28 1016.
- 29
- 30
- 31 32. Dahhan T, Kaushik SS, He M, Mammarrappallil JG, Tapson VF, McAdams HP, Sporn
- 32 TA, Driehuys B, Rajagopal S. Abnormalities in hyperpolarized (129)Xe magnetic
- 33 resonance imaging and spectroscopy in two patients with pulmonary vascular disease.
- 34 *Pulm Circ* 2016;6(1):126-131.
- 35
- 36
- 37
- 38 33. Wang Z, Bier EA, Swaminathan A, Parikh K, Nouis J, He M, Mammarrappallil JG, Luo S,
- 39 Driehuys B, Rajagopal S. Diverse Cardiopulmonary Diseases are Associated with
- 40 Distinct Xenon MRI Signatures. *Eur Respir J* 2019;54(6):1900831.
- 41
- 42
- 43 34. Wang JM, Robertson SH, Wang Z, He M, Virgincar RS, Schrank GM, Smigla RM,
- 44 O'Riordan TG, Sundry J, Ebner L, Rackley CR, McAdams P, Driehuys B. Using
- 45 hyperpolarized (129)Xe MRI to quantify regional gas transfer in idiopathic pulmonary
- 46 fibrosis. *Thorax* 2018;73(1):21-28.
- 47
- 48
- 49 35. Weatherley ND, Stewart NJ, Chan H-F, Austin M, Smith LJ, Collier G, Rao M, Marshall
- 50 H, Norquay G, Renshaw SA, Bianchi SM, Wild JM. Hyperpolarised xenon magnetic
- 51 resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in
- 52 IPF. *Thorax* 2019;74(5):500-502.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 36. Kammerman J, Hahn AD, Cadman RV, Malkus A, Mummy D, Fain SB. Transverse
4 relaxation rates of pulmonary dissolved-phase Hyperpolarized ^{129}Xe as a biomarker of
5 lung injury in idiopathic pulmonary fibrosis. *Magn Reson Med* 2020;84(4):1857-1867.
6
7
- 8 37. Mammarrappallil JG, Rankine L, Wild JM, Driehuys B. New Developments in Imaging
9 Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance
10 Imaging. *J Thorac Imaging* 2019;34(2):136-150.
11
- 12 38. Walkup LL, Thomen RP, Akinyi TG, Watters E, Ruppert K, Clancy JP, Woods JC,
13 Cleveland ZI. Feasibility, tolerability and safety of pediatric hyperpolarized ^{129}Xe
14 magnetic resonance imaging in healthy volunteers and children with cystic fibrosis.
15 *Pediatr Radiol* 2016;46(12):1651-1662.
16
17
- 18 39. Driehuys B, Martinez-Jimenez S, Cleveland ZI, Metz GM, Beaver DM, Nouls JC,
19 Kaushik SS, Firszt R, Willis C, Kelly KT, Wolber J, Kraft M, McAdams HP. Chronic
20 Obstructive Pulmonary Disease: Safety and Tolerability of Hyperpolarized Xe-129 MR
21 Imaging in Healthy Volunteers and Patients. *Radiology* 2012;262(1):279-289.
22
23
- 24 40. Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr GE, Paterson NAM,
25 McCormack DG, Parraga G. Hyperpolarized Xe-129 Magnetic Resonance Imaging:
26 Tolerability in Healthy Volunteers and Subjects with Pulmonary Disease. *Acad Radiol*
27 2012;19(8):941-951.
28
29
- 30 41. Shim YMM, Mata J, Hartwig M, Nakahodo AAA, West K, Emami K, Wadehra N,
31 Cleveland ZI, Walkup L, Woods JC, Dusek A, Mugler J, Driehuys B. Positive Results
32 from Two Randomized Phase III Trials Assessing Hyperpolarized ^{129}Xe Gas MRI as
33 a Measure of Regional Lung Function as Compared to Imaging with ^{133}Xe Gas
34 Scintigraphy. *Am J Respir Crit Care Med* 2020;201:A3265-A3265.
35
36
- 37 42. Shim Y, Mata J, Hartwig M, Aragaki-Nakahodo A, West K, Emami K, Wadehra N,
38 Cleveland Z, Walkup L, Woods J, Dusek A, Mugler J, Driehuys B. Randomized Phase III
39 Trial Assessing Regional Lung Function for Thoracic Resection by Hyperpolarized
40 ^{129}Xe Gas MRI. *Eur Respir J* 2020;56(suppl 64):2080.
41
42
- 43 43. Nikolaou P, Coffey AM, Walkup LL, Gust BM, Whiting N, Newton H, Barcus S, Muradyan
44 I, Dabaghyan M, Moroz GD, Rosen MS, Patz S, Barlow MJ, Chekmenev EY, Goodson
45 BM. Near-unity nuclear polarization with an open-source ^{129}Xe hyperpolarizer for NMR
46 and MRI. *Proc Natl Acad Sci USA* 2013;110(35):14150-14155.
47
48
- 49 44. Birchall JR, Irwin RK, Nikolaou P, Coffey AM, Kidd BE, Murphy M, Molway M, Bales LB,
50 Ranta K, Barlow MJ, Goodson BM, Rosen MS, Chekmenev EY. XeUS: A second-
51
52
53
54
55
56
57
58
59
60

- 1
2
3 generation automated open-source batch-mode clinical-scale hyperpolarizer. *J Magn*
4 *Reson* 2020;319:106813.
5
6 45. Bier EA, Nouls JC, Wang Z, He M, Schrank G, Morales-Medina N, Hashoian R, Svetlik
7 H, Mugler III JP, Driehuys B. A thermally polarized ^{129}Xe phantom for quality assurance
8 in multi-center hyperpolarized gas MRI studies. *Magn Reson Med* 2019;82(5):1961-
9 1968.
10
11 46. Bashir A, Conradi MS, Woods JC, Quirk JD, Yablonskiy DA. Calibration of RF
12 transmitter voltages for hyperpolarized gas MRI. *Magn Reson Med* 2009;61(1):239-243.
13
14 47. Wang Z, He M, Bier E, Rankine L, Schrank G, Rajagopal S, Huang YC, Kelsey C,
15 Womack S, Mammarrappallil J, Driehuys B. Hyperpolarized ^{129}Xe gas transfer MRI: the
16 transition from 1.5T to 3T. *Magn Reson Med* 2018;80(6):2374-2383.
17
18 48. Stewart NJ, Chan H-F, Hughes PJC, Horn FC, Norquay G, Rao M, Yates DP, Ireland
19 RH, Hatton MQ, Tahir BA, Ford P, Swift AJ, Lawson R, Marshall H, Collier GJ, Wild JM.
20 Comparison of (^3He) and (^{129}Xe) MRI for evaluation of lung microstructure and
21 ventilation at 1.5T. *J Magn Reson Imaging* 2018;48(3):632-642.
22
23 49. Stewart NJ, Norquay G, Griffiths PD, Wild JM. Feasibility of human lung ventilation
24 imaging using highly polarized naturally abundant xenon and optimized three-
25 dimensional steady-state free precession. *Magn Reson Med* 2015;74(2):346-352.
26
27 50. Woodhouse N, Wild JM, Paley MNJ, Fichelle S, Said Z, Swift AJ, van Beek EJR.
28 Combined helium-3/proton magnetic resonance imaging measurement of ventilated lung
29 volumes in smokers compared to never-smokers. *J Magn Reson Imaging*
30 2005;21(4):365-369.
31
32 51. Walkup LL, Myers K, El-Bietar J, Nelson A, Willmering MM, Grimley M, Davies SM,
33 Towe C, Woods JC. Xenon-129 MRI detects ventilation deficits in paediatric stem cell
34 transplant patients unable to perform spirometry. *Eur Respir J* 2019;53(5):1801779.
35
36 52. Virgincar RS, Cleveland ZI, Kaushik SS, Freeman MS, Nouls J, Cofer G, Martinez-
37 Jimenez S, He M, Kraft M, Wolber J, McAdams HP, Driehuys B. Quantitative analysis of
38 hyperpolarized ^{129}Xe ventilation imaging in healthy volunteers and subjects with chronic
39 obstructive pulmonary disease. *NMR Biomed* 2013;26(4):424-435.
40
41 53. Ebner L, Virgincar RS, He M, Choudhury KR, Robertson SH, Christe A, Mileto A,
42 Mammarrappallil JG, McAdams HP, Driehuys B, Roos JE. Multireader Determination of
43 Clinically Significant Obstruction Using Hyperpolarized ^{129}Xe -Ventilation MRI.
44 *American Journal of Roentgenology* 2019;212(4):758-765.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 54. Kruger SJ, Niles DJ, Dardzinski B, Harman A, Jarjour NN, Ruddy M, Nagle SK, Francois
4 CJ, Sorkness RL, Burton RM, del Rio AM, Fain SB. Hyperpolarized Helium-3 MRI of
5 exercise-induced bronchoconstriction during challenge and therapy. *J Magn Reson*
6 *Imaging* 2014;39(5):1230-1237.
- 7
8
9 55. van Beek EJR, Dahmen AM, Stavngaard T, Gast KK, Heussel CP, Krummenauer F,
10 Schmiedeskamp J, Wild JM, Søgaard LV, Morbach AE, Schreiber LM, Kauczor H-U.
11 Hyperpolarised ³He MRI versus HRCT in COPD and normal volunteers: PHIL trial. *Eur*
12 *Respir J* 2009;34(6):1311-1321.
- 13
14
15 56. Yablonskiy DA, Sukstanskii AL, Quirk JD. Diffusion lung imaging with hyperpolarized gas
16 MRI. *NMR Biomed* 2017;30(3):e3448.
- 17
18
19 57. Yablonskiy DA, Sukstanskii AL, Quirk JD, Woods JC, Conradi MS. Probing lung
20 microstructure with hyperpolarized noble gas diffusion MRI: theoretical models and
21 experimental results. *Magn Reson Med* 2014;71(2):486-505.
- 22
23
24 58. Ruppert K, Qing K, Patrie JT, Altes TA, Mugler JP, III. Using Hyperpolarized Xenon-129
25 MRI to Quantify Early-Stage Lung Disease in Smokers. *Acad Radiol* 2019;26(3):355-
26 366.
- 27
28
29 59. Kirby M, Svenningsen S, Kanhere N, Owrangi A, Wheatley A, Coxson HO, Santyr GE,
30 Paterson NAM, McCormack DG, Parraga G. Pulmonary ventilation visualized using
31 hyperpolarized helium-3 and xenon-129 magnetic resonance imaging: differences in
32 COPD and relationship to emphysema. *J Appl Physiol* 2013;114(6):707-715.
- 33
34
35 60. Kirby M, Ouriadov A, Svenningsen S, Owrangi A, Wheatley A, Etemad-Rezai R, Santyr
36 GE, McCormack DG, Parraga G. Hyperpolarized ³He and ¹²⁹Xe magnetic resonance
37 imaging apparent diffusion coefficients: physiological relevance in older never- and ex-
38 smokers. *Physiological reports* 2014;2(7):e12068.
- 39
40
41 61. Chan H-F, Collier GJ, Weatherley ND, Wild JM. Comparison of in vivo lung morphometry
42 models from 3D multiple b-value ³He and ¹²⁹Xe diffusion-weighted MRI. *Magn Reson*
43 *Med* 2019;81(5):2959-2971.
- 44
45
46 62. Ouriadov A, Guo F, McCormack DG, Parraga G. Accelerated ¹²⁹Xe MRI morphometry
47 of terminal airspace enlargement: Feasibility in volunteers and those with alpha-1
48 antitrypsin deficiency. *Magn Reson Med* 2020;84(1):416-426.
- 49
50
51 63. Tafti S, Garrison WJ, John P. Mugler I, Shim YM, Altes TA, Mata JF, Lange EEd,
52 Gordon D. Cates J, Ropp AM, Wang C, Miller GW. Emphysema Index Based on
53 Hyperpolarized ³He or ¹²⁹Xe Diffusion MRI: Performance and Comparison with
54 Quantitative CT and Pulmonary Function Tests. *Radiology* 2020;297(1):201-210.
- 55
56
57
58
59
60

- 1
- 2
- 3 64. Chan H-F, Stewart NJ, Norquay G, Collier GJ, Wild JM. 3D diffusion-weighted ^{129}Xe
- 4 MRI for whole lung morphometry. *Magn Reson Med* 2018;79(6):2986-2995.
- 5
- 6 65. Sukstanskii AL, Yablonskiy DA. Lung morphometry with hyperpolarized ^{129}Xe :
- 7 Theoretical background. *Magn Reson Med* 2012;67(3):856-866.
- 8
- 9 66. Ouriadov A, Fox M, Hegarty E, Parraga G, Wong E, Santyr GE. Early Stage Radiation-
- 10 Induced Lung Injury Detected Using Hyperpolarized Xe-129 Morphometry: Proof-of-
- 11 Concept Demonstration in a Rat Model. *Magn Reson Med* 2016;75(6):2421-2431.
- 12
- 13 67. Boudreau M, Xu XJ, Santyr GE. Measurement of ^{129}Xe gas apparent diffusion
- 14 coefficient anisotropy in an elastase-instilled rat model of emphysema. *Magn Reson Med*
- 15 2013;69(1):211-220.
- 16
- 17 68. Niedbalski PJ, Cochran AS, Freeman MS, Guo J, Fugate EM, Davis CB, Dahlke J, Quirk
- 18 JD, Varisco BM, Woods JC, Cleveland ZI. Validating in vivo hyperpolarized ^{129}Xe
- 19 diffusion MRI and diffusion morphometry in the mouse lung. *Magn Reson Med*
- 20 2021;85(4):2160-2173.
- 21
- 22 69. Mata JF, Altes TA, Cai J, Ruppert K, Mitzner W, Hagspiel KD, Patel B, Salerno M,
- 23 Brookeman JR, de Lange EE, Tobias WA, Wang HTJ, Cates GD, Mugler JP. Evaluation
- 24 of emphysema severity and progression in a rabbit model: comparison of hyperpolarized
- 25 He-3 and Xe-129 diffusion MRI with lung morphometry. *J Appl Physiol*
- 26 2007;102(3):1273-1280.
- 27
- 28 70. Chan H-F, Collier GJ, Parra-Robles J, Wild JM. Finite element simulations of
- 29 hyperpolarized gas DWI in micro-CT meshes of acinar airways: validating the cylinder
- 30 and stretched exponential models of lung microstructural length scales. *Magn Reson*
- 31 *Med* 2021;86(1):514-525.
- 32
- 33 71. Niedbalski PJ, Bier EA, Wang Z, Willmering MM, Driehuys B, Cleveland ZI. Mapping
- 34 cardiopulmonary dynamics within the microvasculature of the lungs using dissolved
- 35 ^{129}Xe MRI. *J Appl Physiol* 2020;129(2):218-229.
- 36
- 37 72. Patz S, Muradyan I, Hrovat MI, Dabaghyan M, Washko GR, Hatabu H, Butler JP.
- 38 Diffusion of hyperpolarized ^{129}Xe in the lung: a simplified model of ^{129}Xe septal uptake
- 39 and experimental results. *New Journal of Physics* 2011;13(1):015009.
- 40
- 41 73. Ruppert K, Altes TA, Mata JF, Ruset IC, Hersman FW, Mugler III JP. Detecting
- 42 pulmonary capillary blood pulsations using hyperpolarized xenon-129 chemical shift
- 43 saturation recovery (CSSR) MR spectroscopy. *Magn Reson Med* 2016;75(4):1771-1780.
- 44
- 45 74. Chang YLV. MOXE: A model of gas exchange for hyperpolarized ^{129}Xe magnetic
- 46 resonance of the lung. *Magn Reson Med* 2013;69(3):884-890.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 75. Chang YV, Quirk JD, Ruset IC, Atkinson JJ, Hersman FW, Woods JC. Quantification of
4 human lung structure and physiology using hyperpolarized ^{129}Xe . *Magn Reson Med*
5 2014;71(1):339-344.
6
7
8 76. Patz S, Muradian I, Hrovat MI, Ruset IC, Topulos G, Covrig SD, Frederick E, Hatabu H,
9 Hersman FW, Butler JP. Human pulmonary imaging and spectroscopy with
10 hyperpolarized Xe-129 at 0.2T. *Acad Radiol* 2008;15(6):713-727.
11
12 77. Xie J, Li H, Zhang H, Zhao X, Shi L, Zhang M, Xiao S, Deng H, Wang K, Yang H, Sun X,
13 Wu G, Ye C, Zhou X. Single breath-hold measurement of pulmonary gas exchange and
14 diffusion in humans with hyperpolarized ^{129}Xe MR. *NMR Biomed* 2019;32(5):e4068.
15
16 78. Doganay O, Chen M, Matin T, Rigolli M, Phillips J-A, McIntyre A, Gleeson FV. Magnetic
17 resonance imaging of the time course of hyperpolarized (^{129}Xe) gas exchange in the
18 human lungs and heart. *Eur Radiol* 2019;29(5):2283-2292.
19
20 79. Wang Z, Robertson SH, Wang J, He M, Virgincar RS, Schrank GM, Bier EA, Rajagopal
21 S, Huang YC, O'Riordan TG, Rackley CR, McAdams HP, Driehuys B. Quantitative
22 analysis of hyperpolarized ^{129}Xe gas transfer MRI. *Med Phys* 2017;44(6):2415-2428.
23
24 80. Rankine LJ, Wang Z, Wang JM, He M, McAdams HP, Mammarrappallil J, Rackley CR,
25 Driehuys B, Tighe RM. ^{129}Xe Gas Exchange Magnetic Resonance Imaging as a
26 Potential Prognostic Marker for Progression of Idiopathic Pulmonary Fibrosis. *Ann Am*
27 *Thorac Soc* 2020;17(1):121-125.
28
29 81. Coleman EM, Mummy D, Wang Z, Bier E, Womack S, Korzekwinski J, Mammarrappallil
30 J, Driehuys B, Huang Y-CT. Hyperpolarized ^{129}Xe MRI Identifies Ventilation
31 Responders to Glycopyrrolate/Formoterol Fumarate in Chronic Obstructive Pulmonary
32 Disease. *Am J Respir Crit Care Med* 2020;201:A6429-A6429.
33
34 82. Rajagopal S, Bier E, Wang Z, Parikh K, Almeida-Peters S, Womack S, Nouis J,
35 Mammarrappallil J, Driehuys B. Monitoring Response to Inhaled Prostacyclin Therapy
36 with ^{129}Xe MR Imaging and Spectroscopy in Patients with Pulmonary Hypertension.
37 *Am J Respir Crit Care Med* 2020;201:A3820-A3820.
38
39 83. He M, Robertson SH, Kaushik SS, Freeman MS, Virgincar RS, Davies J, Stiles J, Foster
40 WM, McAdams HP, Driehuys B. Dose and pulse sequence considerations for
41 hyperpolarized ^{129}Xe ventilation MRI. *Magn Reson Imaging* 2015;33(7):877-885.
42
43 84. Hughes PJC, Smith L, Chan H-F, Tahir BA, Norquay G, Collier GJ, Biancardi A, Marshall
44 H, Wild JM. Assessment of the influence of lung inflation state on the quantitative
45 parameters derived from hyperpolarized gas lung ventilation MRI in healthy volunteers. *J*
46 *Appl Physiol* 2019;126(1):183-192.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 85. Halaweish AF, Hoffman EA, Thedens DR, Fuld MK, Sieren JP, Beek EJRv. Effect of
4 Lung Inflation Level on Hyperpolarized ^3He Apparent Diffusion Coefficient
5 Measurements in Never-Smokers. *Radiology* 2013;268(2):572-580.
6
7
8 86. Stewart NJ, Horn FC, Norquay G, Collier GJ, Yates DP, Lawson R, Marshall H, Wild JM.
9 Reproducibility of quantitative indices of lung function and microstructure from ^{129}Xe
10 chemical shift saturation recovery (CSSR) MR spectroscopy. *Magn Reson Med*
11 2017;77(6):2107-2113.
12
13
14 87. Ebner L, Kammerman J, Driehuys B, Schiebler ML, Cadman RV, Fain SB. The role of
15 hyperpolarized (^{129}Xe)xenon in MR imaging of pulmonary function. *Eur J Radiol*
16 2017;86:343-352.
17
18
19 88. Hall CS, Quirk JD, Goss CW, Lew D, Kozlowski J, Thomen RP, Woods JC, Tustison NJ,
20 III JPM, Gallagher L, Koch T, Schechtman KB, Ruset IC, Hersman FW, Castro M.
21 Single-Session Bronchial Thermoplasty Guided by ^{129}Xe Magnetic Resonance Imaging.
22 A Pilot Randomized Controlled Clinical Trial. *Am J Respir Crit Care Med*
23 2020;202(4):524-534.
24
25
26 89. Hahn AD, Kammerman J, Evans M, Zha W, Cadman RV, Meyer K, Sandbo N, Fain SB.
27 Repeatability of regional pulmonary functional metrics of Hyperpolarized ^{129}Xe
28 dissolved-phase MRI. *J Magn Reson Imaging* 2019;50(4):1182-1190.
29
30
31 90. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric Reference Values from a Sample
32 of the General U.S. Population. *Am J Respir Crit Care Med* 1999;159(1):179-187.
33
34
35 91. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson
36 JL, Ip MSM, Zheng J, Stocks J. Multi-ethnic reference values for spirometry for the 3–95-
37 yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40(6):1324-
38 1343.
39
40
41 92. Moller HE, Cleveland ZI, Driehuys B. Relaxation of hyperpolarized ^{129}Xe in a deflating
42 polymer bag. *J Magn Reson* 2011;212(1):109-115.
43
44
45 93. Robertson SH, Virgincar RS, Bier EA, He M, Schrank GM, Smigla RM, Rackley C,
46 McAdams HP, Driehuys B. Uncovering a third dissolved-phase ^{129}Xe resonance in the
47 human lung: Quantifying spectroscopic features in healthy subjects and patients with
48 idiopathic pulmonary fibrosis. *Magn Reson Med* 2017;78(4):1306-1315.
49
50
51 94. Wild JM, Ajraoui S, Deppe MH, Parnell SR, Marshall H, Parra-Robles J, Ireland RH.
52 Synchronous acquisition of hyperpolarised ^3He and ^1H MR images of the lungs –
53 maximising mutual anatomical and functional information. *NMR Biomed* 2011;24(2):130-
54 134.
55
56
57
58
59
60

- 1
2
3 95. Hennig J, Nauerth A, Friedburg H. RARE imaging: A fast imaging method for clinical
4 MR. *Magn Reson Med* 1986;3(6):823-833.
- 5
6 96. Zhang H, Xie J, Xiao S, Zhao X, Zhang M, Shi L, Wang K, Wu G, Sun X, Ye C, Zhou X.
7 Lung morphometry using hyperpolarized ^{129}Xe multi-b diffusion MRI with compressed
8 sensing in healthy subjects and patients with COPD. *Med Phys* 2018;45(7):3097-3108.
- 9
10 97. Tustison NJ, Avants BB, Flors L, Altes TA, de Lange EE, Mugler JP, Gee JC.
11 Ventilation-Based Segmentation of the Lungs Using Hyperpolarized He-3 MRI. *J Magn*
12 *Reson Imaging* 2011;34(4):831-841.
- 13
14 98. Tustison NJ, Avants BB, Lin Z, Feng X, Cullen N, Mata JF, Flors L, Gee JC, Altes TA,
15 Mugler lii JP, Qing K. Convolutional Neural Networks with Template-Based Data
16 Augmentation for Functional Lung Image Quantification. *Acad Radiol* 2019;26(3):412-
17 423.
- 18
19 99. Kirby M, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R,
20 Parraga G. Hyperpolarized He-3 Magnetic Resonance Functional Imaging
21 Semiautomated Segmentation. *Acad Radiol* 2012;19(2):141-152.
- 22
23 100. Parra-Robles J, Marshall H, Hartley R, Brightling C, Wild J. Quantification of Lung
24 Microstructure in Asthma Using a ^3He Fractional Diffusion Approach. *Proc Intl Soc Magn*
25 *Reson Med* 2014;22:3529.
- 26
27 101. Antonacci MA, Zhang L, Degan S, Erdmann D, Branca RT. Calibration of methylene-
28 referenced lipid-dissolved xenon frequency for absolute MR temperature measurements.
29 *Magn Reson Med* 2019;81(2):765-772.
- 30
31 102. Wild JM, Teh K, Woodhouse N, Paley MNJ, Fichele S, de Zanche N, Kasuboski L.
32 Steady-state free precession with hyperpolarized ^3He : Experiments and theory. *J Magn*
33 *Reson* 2006;183(1):13-24.
- 34
35 103. Doganay O, Matin T, Chen M, Kim M, McIntyre A, McGowan DR, Bradley KM, Povey T,
36 Gleeson FV. Time-series hyperpolarized xenon- ^{129}Xe MRI of lobar lung ventilation of
37 COPD in comparison to V/Q-SPECT/CT and CT. *Eur Radiol* 2019;29(8):4058-4067.
- 38
39 104. Doganay O, Matin TN, Mcintyre A, Burns B, Schulte RF, Gleeson FV, Bulte D. Fast
40 dynamic ventilation MRI of hyperpolarized ^{129}Xe using spiral imaging. *Magn Reson*
41 *Med* 2018;79(5):2597-2606.
- 42
43 105. Zanette B, Friedlander Y, Munidasa S, Santyr GE. Comparison of 3D Stack-of-Spirals
44 and 2D Gradient Echo for Ventilation Mapping using Hyperpolarized ^{129}Xe . *Proc Intl*
45 *Soc Mag Reson Med* 2020;28:0449.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

106. Xiao S, Deng H, Duan C, Xie J, Li H, Sun X, Ye C, Zhou X. Highly and Adaptively Undersampling Pattern for Pulmonary Hyperpolarized ^{129}Xe Dynamic MRI. *IEEE Trans Med Imaging* 2019;38(5):1240-1250.
107. Collier GJ, Hughes PJC, Horn FC, Chan H-F, Tahir B, Norquay G, Stewart NJ, Wild JM. Single breath-held acquisition of coregistered 3D ^{129}Xe lung ventilation and anatomical proton images of the human lung with compressed sensing. *Magn Reson Med* 2019;82(1):342-347.
108. Wild JM, Woodhouse N, Paley MNJ, Fichelle S, Said Z, Kasuboski L, van Beek EJR. Comparison between 2D and 3D gradient-echo sequences for MRI of human lung ventilation with hyperpolarized ^3He . *Magn Reson Med* 2004;52(3):673-678.
109. Willmering MM, Niedbalski PJ, Wang H, Walkup LL, Robison RK, Pipe JG, Cleveland ZI, Woods JC. Improved pulmonary ^{129}Xe ventilation imaging via 3D-spiral UTE MRI. *Magn Reson Med* 2020;84(1):312-320.
110. Niedbalski PJ, Willmering MM, Robertson SH, Freeman MS, Loew W, Giaquinto RO, Ireland C, Pratt RG, Dumoulin CL, Woods JC, Cleveland ZI. Mapping and correcting hyperpolarized magnetization decay with radial keyhole imaging. *Magn Reson Med* 2019;82(1):367-376.
111. Marshall H, Ajraoui S, Deppe MH, Parra-Robles J, Wild JM. K-space filter deconvolution and flip angle self-calibration in 2D radial hyperpolarised ^3He lung MRI. *NMR Biomed* 2012;25(2):389-399.
112. Horn FC, Rao M, Stewart NJ, Wild JM. Multiple breath washout of hyperpolarized ^{129}Xe and ^3He in human lungs with three-dimensional balanced steady-state free-precession imaging. *Magn Reson Med* 2017;77(6):2288-2295.
113. Couch MJ, Morgado F, Kanhere N, Kowalik K, Rayment JH, Ratjen F, Santyr G. Assessing the feasibility of hyperpolarized ^{129}Xe multiple-breath washout MRI in pediatric cystic fibrosis. *Magn Reson Med* 2020;84(1):304-311.
114. Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, Gee JC. N4ITK: improved N3 bias correction. *IEEE Trans Med Imaging* 2010;29(6):1310-1320.
115. Miller GW, Altes TA, Brookeman JR, de Lange EE, Mugler JP. Hyperpolarized ^3He lung ventilation imaging with B-1-inhomogeneity correction in a single breath-hold scan. *Magn Reson Mater Phys, Biol Med* 2004;16(5):218-226.
116. Yablonskiy DA, Sukstanskii AL, Woods JC, Gierada DS, Quirk JD, Hogg JC, Cooper JD, Conradi MS. Quantification of lung microstructure with hyperpolarized ^3He diffusion MRI. *J Appl Physiol* 2009;107(4):1258-1265.

- 1
2
3 117. Ruppert K, Amzajerian F, Hamedani H, Xin Y, Loza L, Achekezai T, Duncan IF, Profka
4 H, Siddiqui S, Pourfathi M, Sertic F, Cereda MF, Kadlecek S, Rizi RR. Assessment of flip
5 angle–TR equivalence for standardized dissolved-phase imaging of the lung with
6 hyperpolarized ^{129}Xe MRI. *Magn Reson Med* 2019;81(3):1784-1794.
7
- 8
9 118. Xu XJ, Norquay G, Parnell SR, Deppe MH, Ajraoui S, Hashoian R, Marshall H, Griffiths
10 PD, Parra-Robles J, Wild JM. Hyperpolarized ^{129}Xe gas lung MRI-SNR and
11 T_2^* comparisons at 1.5 T and 3 T. *Magn Reson Med* 2012;68(6):1900-1904.
12
- 13
14 119. Mugler JP, Altes TA, Ruset IC, Miller GW, Mata JF, Qing K, Tsentelovich I, Hersman
15 FW, Ruppert K. Image-based measurement of T_2^* for dissolved-phase Xe^{129} in the
16 human lung. *Proc Intl Soc Mag Reson Med* 2012;20:1347.
17
- 18
19 120. Zanette B, Santyr G. Accelerated interleaved spiral-IDEAL imaging of hyperpolarized
20 ^{129}Xe for parametric gas exchange mapping in humans. *Magn Reson Med*
21 2019;82(3):1113-1119.
22
- 23
24 121. Hahn AD, Kammerman J, Fain SB. Removal of hyperpolarized ^{129}Xe gas-phase
25 contamination in spectroscopic imaging of the lungs. *Magn Reson Med*
26 2018;80(6):2586-2597.
27
- 28
29 122. Willmering MM, Cleveland ZI, Walkup LL, Woods JC. Removal of off-resonance xenon
30 gas artifacts in pulmonary gas-transfer MRI. *Magn Reson Med* 2021;86(2):907-915.
31
- 32
33 123. Fernandes C, Ruppert K, Altes T, Mugler J, 3rd, Ruset I, Miller W, Hersman W, Mata J.
34 Hyperpolarized xenon- 129 3D-Chemical Shift Imaging of the lung in subjects with a
35 history of smoke exposure. *Proc Intl Soc Mag Reson Med* 2013;21:1450-1450.
36
- 37
38 124. Carlson M, Mehrad B, Shim Y, Tustison NJ, Mugler III JP, Altes T, Flors L, Miller G,
39 Mata J. Quantifying Regional Lung Function in Interstitial Lung Disease with
40 Hyperpolarized Xenon- 129 3D SB-CSI. *Proc Intl Soc Magn Reson Med* 2018;26:2480.
41
- 42
43 125. Kern AL, Gutberlet M, Qing K, Voskrebenezov A, Klimeš F, Kaireit TF, Czerner C, Biller
44 H, Wacker F, Ruppert K, Hohlfeld JM, Vogel-Claussen J. Regional investigation of lung
45 function and microstructure parameters by localized ^{129}Xe chemical shift saturation
46 recovery and dissolved-phase imaging: A reproducibility study. *Magn Reson Med*
47 2019;81(1):13-24.
48
- 49
50 126. Rayment JH, Couch MJ, McDonald N, Kanhere N, Manson D, Santyr G, Ratjen F.
51 Hyperpolarised ^{129}Xe magnetic resonance imaging to monitor treatment response in
52 children with cystic fibrosis. *Eur Respir J* 2019;53(5):1802188.
53
54
55
56
57
58
59
60

Figure Captions:

Figure 1. Constituent pieces of a hyperpolarized ^{129}Xe imaging dose. Xenon gas naturally contains 26% ^{129}Xe , but this can be enriched to >80%. This ^{129}Xe is highly polarized and is the portion of the dose that is used for imaging. The remainder of the dose includes other, non-polarized isotopes of xenon and N_2 , used to balance the dose to the desired volume.

Figure 2. Information obtained from the dedicated calibration scan using parameters specified in Table 2. **A** The gas-phase spectrum provides the center frequency for gaseous ^{129}Xe in the lungs. **B** The dissolved spectrum can be fit to provide the amplitude and phase of the RBC and tissue/plasma peaks. From these, the expected RBC/TP ratio and required TE90 can be calculated. **C** The decay of gas signal intensity can be fit to equation 1 to obtain the applied RF flip angle, and the ratio between prescribed and applied flip angle used to calibrate the system. **D** In addition to the calibration information, dissolved spectra can be examined to assess global pulmonary hemodynamics. For clarity, dissolved spectra are smoothed using a sliding window filter and only every 5th spectrum is shown. The dose equivalent delivered to the subject was 39 mL (0.5 L of natural abundance ^{129}Xe polarized to 30%). Data shown in **A** and **B** were fit in the time domain using open source spectroscopy fitting tools in Matlab 2020a (Mathworks, Natick, MA) assuming a Voigt lineshape (93).

Figure 2. Hyperpolarized ^{129}Xe ventilation images acquired in two healthy volunteers using the parameters specified in Table 3. **A** The dose equivalent volume delivered to the subject was 55 mL (0.6 L of natural abundance ^{129}Xe polarized to 35%) and the SNR is 22. **B** The dose equivalent volume delivered to the subject was 100 mL (0.38 L of enriched ^{129}Xe polarized to 33%) and the SNR is 39.

Figure 3. ^1H anatomic images acquired in a healthy volunteer using the parameters specified in Table 4.

Figure 4. Hyperpolarized ^{129}Xe alveolar-airspace size imaging in a healthy volunteer using the diffusion morphometry parameters specified in Table 5. (a) Images with no diffusion weighting ($b = 0 \text{ s/cm}^2$, SNR = 40). (b) Apparent Diffusion Coefficient (ADC) for alveolar-airspace size, based on the $b=12 \text{ s/cm}^2$ diffusion-weighted images (Mean \pm SD = $0.032 \pm 0.009 \text{ cm}^2/\text{s}$). (c) Mean diffusible length scale (L_{mD}) from the stretched exponential model for measurement of mean acinar dimension calculated from four b -values (Mean \pm SD = $271 \pm 61 \mu\text{m}$). The dose equivalent delivered to the subject was 165 mL (0.55 L of enriched ^{129}Xe polarized to 30%).

Figure 6. **A** Conceptual sequence diagram for gas exchange imaging using a radial 1-Point Dixon technique. Radial acquisitions are alternated between the gas and dissolved frequencies, with a 0.5° flip angle used for gas excitation, and a 20° flip angle used for dissolved excitation. **B** Representative gas and dissolved images acquired using the recommended protocol described in Table 6. The dissolved image can subsequently be separated into its constituent RBC and tissue/plasma images.

Tables:

Protocol	Duration	Biomarker	Basic Purpose
Calibration and Spectroscopy	~9 s	Global RBC/TP ¹ , RBC Chemical Shift, RBC Oscillation Amplitude ²	Calibration of center frequency, transmitter power, TE for spectroscopic imaging, global RBC/TP for imaging scans, and quantification of global hemodynamics
Ventilation	~8-12 s	Ventilated volume and defect percent (VDP), Ventilation Heterogeneity	Quantification of ventilation heterogeneity and defects in the lungs
Alveolar-Airspace Size	≤16 s	Apparent Diffusion Coefficient (ADC), Acinar Airway Dimensions	Quantification of pulmonary airway microstructure dimensions
Gas Exchange	≤16 s	Tissue/Plasma Uptake, RBC Transfer, RBC/TP, RBC Oscillation Amplitude	Regional 3D quantification of gas exchange, Tissue/Plasma uptake, RBC transfer, and RBC Signal Oscillation Amplitude
Anatomic Reference	≤16 s	Thoracic Cavity Mask	Provide anatomic reference image for the creation of a thoracic cavity mask, easing xenon image quantification.

Table 1. Imaging protocols and the associated quantitative biomarkers used for hyperpolarized ¹²⁹Xe MRI. Notes: ¹The global RBC/TP refers to the ratio of the spectroscopic signal of xenon dissolved in red blood cells to xenon dissolved in other tissue/plasma. ²The signal from xenon dissolved in red blood cells oscillates with time; the frequency of this oscillation corresponds to the heart rate and its amplitude appears to be sensitive to various disease states. Abbreviations: RBC – Red Blood Cell, TP – Tissue/Plasma, TE – Echo Time, VDP – Ventilation Defect Percentage, ADC – Apparent Diffusion Coefficient.

Parameter	Parameter Value
TR	15 ms
TE ^a	0.45 ms, 0.8 ms (1.5T)
RF Pulse ^b	1 lobed Windowed Sinc (3T), 3 lobed Windowed Sinc (1.5T)
RF Duration ^c	0.65-0.69 ms (3T), 1.15 – 1.25 ms (1.5T)
Flip Angle	20°
RF Frequency	218 ppm, 0 ppm
Dwell Time	39 μs
Bandwidth	25.6kHz
Number of Samples	256
Readout Duration	10 ms
Number of FIDs	500 (dis), 20 (gas)
Gradient Spoiling	15 mT/m-ms (each axis)
Duration	8.4 s

Table 2. Recommended parameters for ¹²⁹Xe flip angle, timing, and center frequency calibration. Notes: ^aTE is measured from the center of the RF pulse to the first point of the FID. ^bThe RF pulse should be the same as used for 1-point Dixon imaging (See Section 3.6). ^cThe duration of the RF pulse should be separately optimized to minimize gas-phase excitation (See Supporting Information S1.4).

Parameter	Parameter Value
Sequence Type	SPGR (GE), T ₁ -FFE (Philips), FLASH (Siemens)
TR	<10 ms
TE	< 5 ms
Flip Angle ^a	8-12°
Slice Thickness	15 mm
Slice Gap	0 mm, 0% (Siemens)
Slice Orientation	Coronal
Slice Order	Sequential – Anterior to Posterior
Phase-encoding Order	Sequential – Left to Right
Phase Undersampling	Not more than 7/8 partial Fourier
Asymmetric Echo	Allowed (62.5% by default)
Number of Slices	Full lung coverage (≥12)
FOV	Full lung coverage
Voxel Size ^b	4 x 4 x 15 mm ³
Rx Bandwidth	7.5-10 kHz (GE), Fat/Water Shift 0.35-0.45 pixels (Philips), 150-200 Hz/pixel (Siemens)
Scan Duration	8-12 s

Table 3. Recommended imaging parameters for ventilation imaging. Where appropriate, vendor-specific parameters have been provided. Notes: ^aImage SNR is optimized by setting the flip angle (α) such that the signal intensity of the center line of k-space is at a maximum: $\alpha = \tan^{-1} \sqrt{\frac{2}{N}}$, where N is the total number of phase encoding steps. ^bSlice thickness can be reduced from 15 mm as needed to ensure that full lung coverage and the desired number of imaging slices are achieved, at sufficiently high SNR.

Parameter	Parameter Value
Sequence Type	SS-FSE (GE), SSH-TSE (Philips), HASTE (Siemens)
TR	Infinite (≤ 1 s between excitations)
TE	< 50 ms
Echo Spacing	3-5 ms
Slice Thickness	15 mm
Slice Gap	0 mm, 0% (Siemens)
Slice Orientation	Coronal
Slice Order	Sequential – Anterior to Posterior
Number of Slices	Full lung coverage
FOV	Full lung coverage
Phase Oversampling	Adequate to suppress aliasing from arms
Phase Undersampling	4/8 partial Fourier
Voxel Size ^a	4 x 4 x 15 mm ³
Rx Bandwidth	65-87 kHz (GE), Fat/Water Shift 1.6-2.0 pixels (Philips), 700-900 Hz/pixel (Siemens)
Scan Duration	≤ 16 s

Table 4. Recommended imaging parameters for anatomical scanning. Where appropriate, vendor-specific parameters are provided. Notes: ^aVoxel size for the anatomical scan should match the ventilation scan as closely as possible. Similarly, the geometry prescription should be copied from the ventilation scan to ensure that the slices for the two scans are in the same location. In some cases, vendor specific limitations may prevent imaging ¹H with the coarse resolution specified here. In this case, the voxel size should be set to 2 x 2 x 15 mm³ or some other suitable fractional resolution of the ¹²⁹Xe scan.

Parameter	Parameter Value	
	ADC imaging (2D)	Diffusion morphometry (3D)
Sequence Type	SPGR (GE), T ₁ -FFE (Philips), FLASH (Siemens)	
TR	<20 ms	
TE	<15 ms	
Flip Angle	3-5°	
Slice Thickness	30 mm	15 mm
Slice Gap	0 mm, 0% (Siemens)	
Slice Orientation	Coronal	
Slice Order	Sequential – Anterior to Posterior	
Phase-encoding Order	Center-out	
Number of Slices	Full lung coverage (≤9)	Full lung coverage (≤18)
FOV	Full lung coverage (~40 cm)	
b-values	0, 12 s/cm ²	0, 12, 20, 30 s/cm ²
Diffusion Time (Δ)	8.5 ms	
Gradient flat time	2.3 ms	
Gradient separation time	5.6 ms	
Gradient ramp time	0.3 ms	
Voxel Size	6 x 6 x 30 mm ³	6 x 6 x 15 mm ³
Rx Bandwidth	10 - 20 kHz (GE), Fat/Water Shift: 0.35-0.7 pixels (Philips), 150-300 Hz/pixel (Siemens)	
Acceleration	Fully sampled	CS 4x undersampling
Scan Duration	≤ 16 s	

Table 5. Recommended parameters for diffusion weighted imaging. Vendor specific parameters are supplied where appropriate.

Parameter	Parameter Value
Sequence Type	3D Radial
Base Resolution	64 x 64 x 64
FOV	400 x 400 x 400 mm ³
Points per Radial Arm	64
Bandwidth	25 kHz (GE), Fat/Water Shift: 1.78 pixels (Philips), 781 Hz/Pixel (Siemens)
Read-out Duration	0.64 ms
Radial projections	1000/1000 (gas/dissolved)
TR ^a	15 ms
TE ^b	TE ₉₀
Flip Angle	0.5°/20° (gas/dissolved)
RF Pulse	1 lobed Windowed Sinc (3T), 3 lobed Windowed Sinc (1.5T)
RF Duration ^c	0.65-0.69 ms (3T), 1.15 – 1.25 ms (1.5T)
RF Frequency	0 ppm/218 ppm (gas/dissolved)
Gradient Ramp	100 μs (Data sampled during ramp)
Projection Ordering	Halton-Randomized Archimedean Spiral
Gradient Spoiling	Minimum 19 mT/m-ms on x-axis
Scan Duration	16 s

Table 6. Recommended parameters for gas exchange imaging using the 1-point Dixon technique. Vendor-specific parameters are provided where appropriate. Notes: ^aTR is given as the time between subsequent projections acquired at the same frequency (i.e. gas-to-gas or dissolved-to-dissolved). Acquisition is interleaved such that the time between excitations is 7.5 ms. ^bAt 3T (1.5T), TE₉₀ should be in the range 0.45-0.50 (0.8-1.1) ms. Should the calibration be unavailable or return a value outside of that range, a TE of 0.47 (1.0) ms can be used. ^cThis pulse length should be the same as used in the calibration sequence and should be calibrated to minimize off-resonance gas phase excitation (Supporting Information S1.4).

Parameter	Parameter Value
Sequence Type	3D Radial
Base Resolution	64 x 64 x 64
FOV	400 x 400 x 400mm ³
Points per Radial Arm	64
Bandwidth	25 kHz (GE), Fat/Water Shift: 1.78 pixels (Philips), 781 Hz/Pixel (Siemens)
Read-out Duration	1.28 ms
Radial projections	4600
TR	Minimum (Target ~2.5 ms)
TE	Minimum (Target ~0.3 ms)
Flip Angle	5°
RF Pulse	Hard Pulse
RF Duration	0.5 ms
Gradient Ramp	100 μ s (Data sampled during ramp)
Projection Ordering	Halton-Randomized Archimedean Spiral
Gradient Spoiling	Minimum of 10 mT/m-ms on x-axis
Scan Duration	12 s

Table 7. Recommended imaging parameters for the ¹H anatomical scan to be acquired immediately following the ¹²⁹Xe gas exchange image.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Constituent pieces of a hyperpolarized ^{129}Xe imaging dose. Xenon gas naturally contains 26% ^{129}Xe , but this can be enriched to >80%. This ^{129}Xe is highly polarized and is the portion of the dose that is used for imaging. The remainder of the dose includes other, non-polarized isotopes of xenon and N_2 , used to balance the dose to the desire volume.




Figure 2. Information obtained from the dedicated calibration scan using parameters specified in Table 2. **A** The gas-phase spectrum provides the center frequency for gaseous ^{129}Xe in the lungs. **B** The dissolved spectrum can be fit to provide the amplitude and phase of the RBC and tissue/plasma peaks. From these, the expected RBC/TP ratio and required TE90 can be calculated. **C** The decay of gas signal intensity can be fit to equation 1 to obtain the applied RF flip angle, and the ratio between prescribed and applied flip angle used to calibrate the system. **D** In addition to the calibration information, dissolved spectra can be examined to assess global pulmonary hemodynamics. For clarity, dissolved spectra are smoothed using a sliding window filter and only every 5th spectrum is shown. The dose equivalent delivered to the subject was 39 mL (0.5 L of natural abundance ^{129}Xe polarized to 30%). Data shown in A and B were fit in the time domain using open source spectroscopy fitting tools in Matlab 2020a (Mathworks, Natick, MA) assuming a Voigt lineshape (93).

164x108mm (300 x 300 DPI)




Figure 3. Hyperpolarized ^{129}Xe ventilation images acquired in two healthy volunteers using the parameters specified in Table 3. A The dose equivalent volume delivered to the subject was 55 mL (0.6 L of natural abundance ^{129}Xe polarized to 35%) and the SNR is 22. B The dose equivalent volume delivered to the subject was 100 mL (0.38 L of enriched ^{129}Xe polarized to 33%) and the SNR is 39.




Figure 4. ^1H anatomic images acquired in a healthy volunteer using the parameters specified in Table 5.




Figure 5. Hyperpolarized ^{129}Xe alveolar-airspace size imaging in a healthy volunteer using the diffusion morphometry parameters specified in Table 5. (a) Images with no diffusion weighting ($b = 0 \text{ s/cm}^2$, $\text{SNR} = 40$). (b) Apparent Diffusion Coefficient (ADC) for alveolar-airspace size, based on the $b=12 \text{ s/cm}^2$ diffusion-weighted images ($\text{Mean} \pm \text{SD} = 0.032 \pm 0.009 \text{ cm}^2/\text{s}$). (c) Mean diffusive length scale (L_{mD}) from the stretched exponential model for measurement of mean acinar dimension calculated from four b -values ($\text{Mean} \pm \text{SD} = 271 \pm 61 \mu\text{m}$). The dose equivalent delivered to the subject was 165 mL (0.55 L of enriched ^{129}Xe polarized to 30%).

175x181mm (300 x 300 DPI)




Figure 6. **A** Conceptual sequence diagram for gas exchange imaging using a radial 1-Point Dixon technique. Radial acquisitions are alternated between the gas and dissolved frequencies, with a 0.5° flip angle used for gas excitation, and a 20° flip angle used for dissolved excitation. **B** Representative gas and dissolved images acquired using the recommended protocol described in Table 6. The dissolved image can subsequently be separated into its constituent RBC and tissue/plasma images.

171x63mm (300 x 300 DPI)

1
2
3 **Protocols for Multi-Site Trials using Hyperpolarized ^{129}Xe MRI for Imaging of Ventilation,**
4 **Alveolar-airspace size, and Gas Exchange: A Position Paper from the ^{129}Xe MRI Clinical**
5 **Trials Consortium**
6

7 Peter J. Niedbalski^{1*}, Chase S. Hall¹, Mario Castro¹, Rachel L. Eddy², Jonathan H. Rayment³,
8 Sarah Svenningsen³, Grace Parraga⁴, Brandon Zanette⁵, Giles E. Santyr^{5,6}, Robert P. Thomen⁷,
9 Neil J. Stewart⁸, Guilhem J. Collier⁸, Ho-Fung Chan⁸, Jim M. Wild⁸, Sean B. Fain⁹, G. Wilson
10 Miller¹⁰, Jaime F. Mata¹⁰, John P. Mugler III¹⁰, Bastiaan Driehuys¹¹, Matthew M. Willmering¹²,
11 Zackary I. Cleveland^{12,13}, Jason C. Woods^{12,13}
12

13 ¹Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas Medical Center,
14 Kansas City, Kansas, USA
15

16 ²Centre for Heart Lung Innovation, St. Paul's Hospital; Division of Respiratory Medicine,
17 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
18

19 ³Division of Respiratory Medicine, Department of Pediatrics, University of British Columbia,
20 Vancouver, British Columbia, Canada
21

22 ³Firestone Institute for Respiratory Health, St Joseph's Healthcare; Department of Medicine,
23 Division of Respiriology, McMaster University, Hamilton, Ontario, Canada
24

25 ⁴Robarts Research Institute, Western University, London, Ontario, Canada.
26

27 ⁵Translational Medicine Program, Hospital for Sick Children, Toronto, Ontario, Canada.
28

29 ⁶Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
30

31 ⁷Departments of Radiology and Bioengineering, University of Missouri, Columbia, Missouri, USA
32

33 ⁸POLARIS, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield,
34 Sheffield, UK
35

36 ⁹Departments of Medical Physics, Radiology, and Biomedical Engineering, University of
37 Wisconsin, Madison, Wisconsin, USA
38

39 ¹⁰Center for In-vivo Hyperpolarized Gas MR Imaging, Department of Radiology and Medical
40 Imaging, University of Virginia, Charlottesville, Virginia, USA
41

42 ¹¹Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA
43

44 ¹²Center for Pulmonary Imaging Research, Cincinnati Children's Hospital Medical Center,
45 Cincinnati, Ohio, USA
46

47 ¹³Departments of Pediatrics (Pulmonary Medicine) and Radiology, Cincinnati Children's Hospital
48 Medical Center, Cincinnati, Ohio, USA
49

50
51
52
53
54
55
56
57
58
59
60

*Corresponding Author:

Peter J. Niedbalski
3901 Rainbow Blvd. Lied 3043
Kansas City, KS 66160
pniedbalski@kumc.edu

S1 SUPPORTING INFORMATION

S1.1 Quality Control and Calibration using a Boltzmann-Polarized Phantom

Prior to imaging hyperpolarized ^{129}Xe , it is useful to image a thermally polarized phantom to ensure that the multi-nuclear functions of the scanner are operational and that the imaging coil and its connections are functional. Often, a pressurized phantom is created in-house and used to ensure intra-site scan-to-scan consistency (1). More recently, Bier et al. developed a phantom that contains a large amount of xenon gas (41 L of natural abundance xenon at standard temperature and pressure) at high pressure (11.6 bar), making it suitable for both spectroscopic- and imaging-based quality control (2). This phantom has a T_1 of 580 ms, and a single-shot NMR spectrum of the phantom using a 90° pulse yields an SNR of ~ 15 . This phantom is currently the only commercially available xenon phantom for MRI applications. Homebuilt or future alternative commercial phantoms may be similarly useful for multi-site quality control. We recommend acquiring a suitable phantom that can be used for quality control and to better compare results across institutions.

The standard pre-scan calibration that should be performed prior to every hyperpolarized ^{129}Xe imaging study should include a basic spectroscopy experiment and, if the phantom in use allows, a short imaging scan. Images can then be stored to monitor scanner performance over time. For spectroscopy, nearly any basic FID sequence will be adequate to ensure signal is present and to ascertain the center frequency. Optionally, the flip angle could be calibrated using a series of RF pulses with increasing power or duration. Once center frequency and flip angle are established, the phantom can be imaged using a 2D spoiled GRE with relatively coarse resolution. Suggested standardized parameters are shown in Table S1. For these suggested parameters, a 2D projection image with SNR >10 can be acquired in about 3 minutes.

Parameter	Parameter Value
Sequence Type	SPGR (GE), T_1 -FFE (Philips), FLASH (Siemens)
TR	750 ms
TE	6.13 ms (or shortest possible)
Flip Angle	Ernst Angle: 74° (3T), 76° (1.5T)
Matrix	64 x 32
FOV	440 x 440 mm ²
Readout Undersampling	Asymmetric Readout (42/64 coverage)
Slice Orientation	Coronal
Phase-encoding Order	Sequential - Left to Right
Rx Bandwidth	4 kHz (GE), Fat/Water Shift 29.4 pixels (Philips), 60 Hz/pixel (Siemens)
Averages	8
Scan Duration	3.2 minutes

Table S1. Suggested imaging parameters for quality control imaging of a standardized xenon phantom.

S1.2 Instrumentation and Technical Considerations

While the current position paper is primarily concerned with imaging methodology, it is necessary to provide some background on the technical requirements of hyperpolarized ^{129}Xe MRI. Specifically, four main pieces of instrumentation are required for HP ^{129}Xe MRI: Polarizer, Polarimeter, Multi-nuclear MRI scanner, and RF coil. Currently, there are commercial suppliers of xenon hyperpolarization systems that produce instruments that are easily used and provide high ^{129}Xe polarization in a clinically useful timeframe. Beyond these commercial options, a number of groups have published designs for home-built polarizer systems, many of which provide excellent performance for human imaging (1,3-8).

A polarimeter is also needed to measure the xenon polarization of doses prior to delivery to subjects. The polarimeter should utilize a strong enough magnetic field (≥ 2 mT) that xenon doses can be stored without excessive T_1 relaxation prior to delivery to the subject. Polarimeters for hyperpolarized ^{129}Xe are commercially available or can be built in-house.

In addition to a hyperpolarization system, an MRI scanner with multi-nuclear capability is needed for imaging. While most clinical MRI scanners are not natively equipped with multi-nuclear imaging, such packages can be added to most high-end models. Many research-dedicated scanners have this functionality. Currently, most new multi-nuclear MRI scanners in production have a magnetic field strength of 3T, though there are a number of sites with 1.5T multi-nuclear scanners in use for HP ^{129}Xe MRI. Imaging at 1.5T provides better magnetic field homogeneity and longer T_2^* relaxation times, while imaging at 3T is more broadly available and provides higher image SNR (9,10). The imaging protocol recommendations provided in this position paper are equally applicable at both of these standard magnetic field strengths. Note that for gas exchange imaging, some parameters required different settings at the two field strengths. In this case, parameters for both 1.5T and 3T are included in the recommendations.

Finally, a dedicated RF coil is needed for excitation and acquisition of the hyperpolarized ^{129}Xe signal. As with polarizer systems, there are a number of commercial and homebuilt options, including saddle coils (11), birdcage coils (12-14), flexible vest transmit-receive coils (2), and transmit only coils with multiple receiver arrays. Any of these imaging coils can produce quality images when imaging following the below recommendations. Of note, flexible vest coils were used in the recent phase III clinical trials and are the only coils that will be FDA approved initially.

S1.3 Subject Positioning and Physiological Monitoring

Subjects should be placed in the MRI scanner with their lungs as close to magnet isocenter as possible. Position should be verified using standard ^1H localization imaging sequences. It is helpful to place a mark on the xenon imaging coil and use this as a landmark in order to consistently place subjects in the correct position. Xenon imaging coils should be centered on the lungs in order to avoid signal reductions at the apex or base of the lungs. For small subjects (e.g. pediatrics, petite adults), it is often comfortable for a subject to have their arms at their sides during imaging. For particularly small subjects imaged using a flexible vest coil, it may be beneficial to use an additional coil insert to maintain coil shape. For larger subjects, it is often preferable to have the subject rest their arms above their heads; for these subjects, having their arms by their sides can either deform a flexible chest coil (such as is used at many HP ^{129}Xe MRI sites) which can impact xenon image quality, or lead to signal wrap in anatomic images.

1
2
3 Because the hyperpolarized xenon imaging process involves a breath hold of an anoxic xenon
4 mixture, care should be taken to ensure subject safety. At the proposed concentrations xenon is
5 known to have mild paresthetic effects, though these are transient for the volumes and breath
6 hold durations used for imaging (15-17). There are currently many methods in use for physiologic
7 monitoring of imaging subjects. At a minimum, we recommend that subjects' oxygen saturation
8 (SPO_2) and heart rate be monitored before, during, and after xenon breath-hold using an MR safe
9 pulse oximeter. A slight transient decrease ($<10\%$) in SPO_2 or a slight increase in heart rate (<20
10 beats per min) are common side effects immediately following a xenon breath-hold. Additional
11 symptoms may include mild euphoria or tingling of extremities. Additional xenon doses should not
12 be administered before returning to stable baseline (SPO_2 within 5% of its baseline value) and all
13 xenon-related side effects have subsided. In addition to SPO_2 and heart rate monitoring, subjects
14 should be asked to give a subjective assessment of their condition. Supplemental oxygen should
15 be available to provide to subjects as needed to maintain O_2 saturation. If supplemental oxygen
16 is already provided, its use can be discontinued for the preparatory breaths prior to the next xenon
17 inhalation (see Supporting Information S1.4) to avoid gas depolarization effects.

21 **S1.4 Optimization of RF Pulse to Minimize Gas Phase Excitation**

22 For dissolved phase imaging, a large concern is minimizing off-resonance gas phase excitation
23 that can contaminate images of the dissolved-phase compartments. Minimizing gas-phase
24 excitation can be challenging, due to the relative size of the gaseous magnetization pool (~ 100 -
25 fold stronger signal than dissolved phase) and the short T_2^* of dissolved phase ^{129}Xe , which limits
26 the pulse duration. Currently, our recommendation is to perform 1-point Dixon imaging using a
27 windowed 1(3)-lobe sinc pulse at 3T(1.5T), which provides generally good frequency selective
28 excitation of the dissolved peaks. Scanner specific RF amplifier imperfections, however, will
29 contribute to unwanted gas-phase excitation. As such, the off-resonance excitation of gaseous
30 xenon should be calibrated prior to imaging studies. This calibration can be performed once and
31 used for all imaging unless substantial changes are made to the RF chain (swap RF amplifier,
32 use a different coil), at which point the calibration should be repeated.

33 To perform this calibration, the transmitter and receiver frequency should be set to 218 ppm above
34 the gas phase frequency. Using a spectroscopy sequence with a high receiver bandwidth (>20
35 MHz), a series of spectra should be acquired from a bag of hyperpolarized xenon using pulse
36 durations between 0.60 and 0.75 ms (3T) or 1.1 and 1.3 ms (1.5T). For each of these spectra,
37 the gas-phase signal intensity should be analyzed, and the pulse length for all subsequent
38 calibration and gas exchange imaging should be set to the pulse length for which gas-phase
39 contamination was minimized. For further details into this calibration, see the description provided
40 by Wang et al. (10).

46 **S1.5 Coaching for Xenon Inhalation**

47 To ensure that all subjects inhale the dose of hyperpolarized xenon from a similar lung inflation
48 that is close to FRC, they should be coached to inhale and exhale normally (at tidal volume (TV))
49 prior to inhalation of HP xenon. A variety of coaching methods are currently in use for the breath-
50 hold procedure and a consensus statement will likely be the subject of a future consortium paper.
51 One simple coaching method in use at several HP ^{129}Xe MRI sites is as follows:

- 54 • Take a regular breath in.
 - 55 • Breathe it out.
- 56
57
58
59
60

- Take a regular breath in.
- Breathe it out. (*Hold dose bag where subject can inhale from it*)
- Breathe in. Breathe in. Breathe in. Hold your breath. Go!

We highly recommend practicing the breathing maneuver outside of the magnet prior to scanning using a bag of air with its volume matched to the xenon dose. Many sites find it useful to use nose clips to ensure that subjects do not inhale or prematurely exhale through their nose. It is also essential for the person delivering the gas to watch the subject's chest to confirm that their breathing is in sync with the instructions.

Following the imaging breath-hold, it can be helpful to coach subjects to take several deep breaths in and out. This can facilitate the removal of xenon from their lungs and the rapid resolution of transient declines in oxygen saturation or other small side effects.

References

1. Nikolaou P, Coffey AM, Walkup LL, Gust BM, Whiting N, Newton H, Barcus S, Muradyan I, Dabaghyan M, Moroz GD, Rosen MS, Patz S, Barlow MJ, Chekmenev EY, Goodson BM. Near-unity nuclear polarization with an open-source ^{129}Xe hyperpolarizer for NMR and MRI. *Proc Natl Acad Sci USA* 2013;110(35):14150-14155.
2. Bier EA, Nouls JC, Wang Z, He M, Schrank G, Morales-Medina N, Hashoian R, Svetlik H, Mugler III JP, Driehuys B. A thermally polarized ^{129}Xe phantom for quality assurance in multi-center hyperpolarized gas MRI studies. *Magn Reson Med* 2019;82(5):1961-1968.
3. Nikolaou P, Coffey AM, Walkup LL, Gust BM, Whiting N, Newton H, Muradyan I, Dabaghyan M, Ranta K, Moroz GD, Rosen MS, Patz S, Barlow MJ, Chekmenev EY, Goodson BM. XeNA: an automated 'open-source' (^{129}Xe) hyperpolarizer for clinical use. *Magn Reson Imaging* 2014;32(5):541-550.
4. Korchak SE, Kilian W, Mitschang L. Configuration and Performance of a Mobile ^{129}Xe Polarizer. *Appl Magn Reson* 2013;44(1):65-80.
5. Norquay G, Parnell SR, Xu X, Parra-Robles J, Wild JM. Optimized production of hyperpolarized ^{129}Xe at 2 bars for in vivo lung magnetic resonance imaging. *J Appl Phys* 2013;113(4):044908.
6. Ruset IC, Ketel S, Hersman FW. Optical pumping system design for large production of hyperpolarized Xe-129. *Phys Rev Lett* 2006;96(5):053002-053001 - 053002-053004.
7. Birchall JR, Irwin RK, Nikolaou P, Coffey AM, Kidd BE, Murphy M, Molway M, Bales LB, Ranta K, Barlow MJ, Goodson BM, Rosen MS, Chekmenev EY. XeUS: A second-generation automated open-source batch-mode clinical-scale hyperpolarizer. *J Magn Reson* 2020;319:106813.
8. Norquay G, Collier GJ, Rao M, Stewart NJ, Wild JM. ^{129}Xe -Rb Spin-Exchange Optical Pumping with High Photon Efficiency. *Phys Rev Lett* 2018;121(15):153201.
9. Xu XJ, Norquay G, Parnell SR, Deppe MH, Ajraoui S, Hashoian R, Marshall H, Griffiths PD, Parra-Robles J, Wild JM. Hyperpolarized ^{129}Xe gas lung MRI-SNR and $T2^*$ comparisons at 1.5 T and 3 T. *Magn Reson Med* 2012;68(6):1900-1904.
10. Wang Z, He M, Bier E, Rankine L, Schrank G, Rajagopal S, Huang YC, Kelsey C, Womack S, Mammarrappallil J, Driehuys B. Hyperpolarized ^{129}Xe gas transfer MRI: the transition from 1.5T to 3T. *Magn Reson Med* 2018;80(6):2374-2383.

11. Loew W, Thomen RP, Giaquinto RO, Pratt RG, Cleveland ZI, Walkup LL, Dumoulin CL, Woods JC. A Dual Loop T/R-Xenon Coil for Homogenous Excitation with Improved Comfort and Size. 2016. p 1624.
12. Dregely I, Ruset IC, Wiggins G, Mareyam A, Mugler JP, Altes TA, Meyer C, Ruppert K, Wald LL, Hersman FW. 32-channel phased-array receive with asymmetric birdcage transmit coil for hyperpolarized xenon-129 lung imaging. *Magn Reson Med* 2013;70(2):576-583.
13. Xu X, Deppe MH, De Zanche N, Wild JM. An Asymmetric Insert Quadrature Birdcage Coil for Hyperpolarised 129Xe Lung MRI at 1.5 T. *Proc Intl Soc Mag Reson Med* 2012;20:2625.
14. Farag A, Wang J, Ouriadov A, Parraga G, Santyr GE. Unshielded and Asymmetric RF Transmit Coil for Hyperpolarized 129Xe Human Lung Imaging at 3.0 T *Proc Intl Soc Mag Reson Med* 2012;20:1361.
15. Driehuys B, Martinez-Jimenez S, Cleveland ZI, Metz GM, Beaver DM, Nouls JC, Kaushik SS, Firszt R, Willis C, Kelly KT, Wolber J, Kraft M, McAdams HP. Chronic Obstructive Pulmonary Disease: Safety and Tolerability of Hyperpolarized Xe-129 MR Imaging in Healthy Volunteers and Patients. *Radiology* 2012;262(1):279-289.
16. Walkup LL, Thomen RP, Akinyi TG, Watters E, Ruppert K, Clancy JP, Woods JC, Cleveland ZI. Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis. *Pediatr Radiol* 2016;46(12):1651-1662.
17. Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr GE, Paterson NAM, McCormack DG, Parraga G. Hyperpolarized Xe-129 Magnetic Resonance Imaging: Tolerability in Healthy Volunteers and Subjects with Pulmonary Disease. *Acad Radiol* 2012;19(8):941-951.